



Curcumin and chemokines: mechanism of action and therapeutic potential in inflammatory diseases

Mahvash Sadeghi¹ · Sajad Dehnavi^{2,3} · Ali Asadirad² · Suowen Xu⁴ · Muhammed Majeed⁵ · Tannaz Jamialahmadi^{6,7} · Thomas P. Johnston⁸ · Amirhossein Sahebkar^{7,9,10,11}

Received: 15 July 2022 / Accepted: 9 January 2023 / Published online: 30 March 2023
© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2023

Abstract

Chemokines belong to the family of cytokines with chemoattractant properties that regulate chemotaxis and leukocyte migration, as well as the induction of angiogenesis and maintenance of hemostasis. Curcumin, the major component of the *Curcuma longa rhizome*, has various pharmacological actions, including anti-inflammatory, immune-regulatory, anti-oxidative, and lipid-modifying properties. Chemokines and chemokine receptors are influenced/modulated by curcumin. Thus, the current review focuses on the molecular mechanisms associated with curcumin's effects on chemoattractant cytokines, as well as putting into context the many studies that have reported curcumin-mediated regulatory effects on inflammatory conditions in the organs/systems of the body (e.g., the central nervous system, liver, and cardiovascular system). Curcumin's effects on viral and bacterial infections, cancer, and adverse pregnancy outcomes are also reviewed.

Keywords Curcumin · Chemokine · Cytokine · Inflammation · Cancer · Infection

Introduction

Chemokines are small (7–13 kDa), signaling proteins that belong to the cytokine family and exert chemoattractant properties. They play an important role in both physiologic and pathological immune responses through the formation of concentration gradients and interactions with their respective receptors on cell surfaces. Almost fifty different chemokines have been identified in humans that induce hemostasis, angiogenesis and regulate chemotaxis and leukocyte adhesion/

transmigration. The chemokines are grouped into CC, CXC, CX3C, and XC subfamilies according to the number of amino acids located between the first two structural cysteine residues (Deshmane et al. 2009; Bodnar 2015; Gustavsson 2020). Chemokine receptors are expressed on various cell types, including leukocytes and other non-hematopoietic cells. About twenty types of chemokine receptors have been identified that are 7-transmembrane G protein-coupled receptors (GPCRs). The binding of chemokine to its receptor creates a calcium signaling cascade, activating small

✉ Amirhossein Sahebkar
sahebkar@mums.ac.ir; amir_saheb2000@yahoo.com

¹ Department of Immunology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

² Department of Immunology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

³ Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

⁴ Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China

⁵ Sabinsa Corporation, East Windsor, NJ, USA

⁶ Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

⁷ Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

⁸ Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO, USA

⁹ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

¹⁰ School of Medicine, The University of Western Australia, Perth, Australia

¹¹ Department of Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, P.O. Box, Mashhad 91779-48564, Iran

GTPases. Activation of integrins and actin polymerization are the downstream events that result in the development of a pseudopod, polarized cell morphology, and ultimately cell movement. The chemokines are then internalized via clathrin-based endocytosis (Cabrero-de las Heras and Martínez-Balibrea 2018; Rajagopal et al. 2010; Proudfoot and Ugucioni 2016). Cascade-activation of downstream signaling proteins is associated with inflammatory processes and leukocyte accumulation in infected or injured tissues. This process is a key step in cell migration and a powerful 'check-point' in regulating cell migration. Thus, intentional regulation of cell migration could potentially be accomplished using different therapeutic agents or strategies (Marchese 2014; Maryam Saberi Karimian et al. 2017a; Scholten et al. 2012) (Table 1).

Curcumin (diferuloylmethane) is a natural polyphenol from the herb, turmeric. The chemical formula and chemical name are $C_{21}H_{20}O_6$ and 1, 7-bis-(4-hydroxy-3-methoxyphenyl)-hepta-1, 6-diene-3, 5-dione, respectively (Shatadal Ghosh et al. 2015; Prasad et al. 2014; Yadollahi and Zargaran 2019), respectively. A molecule of curcumin has a symmetric structure, including two parallel aromatic rings and O-methoxy phenolic groups that are bound to a carbon linker, which has an α , β -unsaturated β -diketone moiety (Yu et al. 2019). Curcumin is the major component of *Curcuma longa* rhizome (turmeric; Zingiberaceae), a perennial plant, which has been used as a spice in cooking and used in traditional Chinese and Indian natural medicine therapy for centuries. In traditional Asian medicine, curcumin is used to treat various disorders, including rheumatism, liver disorders, insect bites, cough, sinusitis, and anorexia (Bahrami et al. 2019; Mohammad Mohajeri et al. 2018). Curcumin is a safe phytochemical that elicits a wide range of biological actions in the human body. It shows anti-inflammatory, antioxidant, lipid-modulating, anti-thrombotic, immunomodulatory, hepatoprotective, anti-diabetic, anti-tumor, and neuroprotective actions (Qadir et al. 2016; Bavarsad et al. 2019; Ghasemi et al. 2019; Iranshahi et al. 2009; Panahi et al. 2017b; Parsamanesh et al. 2018; Sahebkar and Henrotin 2016; Alidadi et al. 2020; Heidari et al. 2022; Vahedian-Azimi et al. 2022; Mohammed et al. 2021).

In addition, curcumin influences various cells and molecular targets like growth factors, cytokines/chemokines, hormones, transcription factors, cell adhesion molecules, protein kinases, redox state enzymes, and receptors (Esatbeyoglu et al. 2012; H. Zhou et al. 2011; Mashayekhi-Sardoo et al. 2021; Mohajeri et al. 2020; Soltani et al. 2021; Ganjali et al. 2017b; Momtazi-Borojeni et al. 2018). The anti-inflammatory effects of curcumin are mediated by down-regulation in the activity of cyclooxygenase-2 (COX-2), lipoxygenase (LOX), inflammasome, and inducible nitric oxide synthase (iNOS) (Goel et al. 2008b, 2008a; Hassanzadeh et al. 2020). Moreover, curcumin also inhibits IL-2,

IL-6, IL-8, IL-12, TNF- α , macrophage inhibitory protein (MIP), and the production of monocyte chemoattractant protein-1 (MCP-1) pro-inflammatory cytokines and chemokines (Abe et al. 1999), as well as down-regulates mitogen-activated and janus kinases (Natarajan and Bright 2002; Siwak et al. 2005). These biological effects appear to be achieved by curcumin-mediated inhibition of NF- κ B (Surh et al. 2001; Zhong et al. 2012; Lee et al. 2005; Ji et al. 2009; Zhao et al. 2014).

The current review discusses curcumin's anti-inflammatory and regulatory effects on chemokines and chemokine receptors in various in vitro and in vivo (human and experimental animal models) studies in different medical conditions and diseases.

Inhibitory effects of curcumin on chemokines

CCL2 (MCP-1) (Fig. 1)

CCL2 or monocyte chemoattractant/chemotactic protein-1 (MCP-1) is the major chemotactic protein for monocytes (Mohammadi et al. 2019). Inhibition of CCL2 function may reduce immune cell attraction to inflammation sites and slow the inflammatory response's progression. Curcumin was shown to inhibit MCP-1 production in different cell types and attenuate monocyte recruitment (Abe et al. 1999; Young et al. 2014; Karimian et al. 2017b; Liu et al. 2014; Huang et al. 2016; Jain et al. 2009; Tu et al. 2012; Pan et al. 2013a). In addition, studies with animal models have shown that curcumin reduces MCP-1 expression and alleviates inflammatory disorders, although human studies are limited (Maryam Saberi Karimian et al. 2017a).

Most preclinical studies have reported that curcumin exerts its effects by regulating the MAPK and NF- κ B signaling pathways (Panahi et al. 2017a; Antoine et al. 2013; Nagaraju et al. 2015; Zhao et al. 2015; Kim et al. 2005; Cao et al. 2015; Bukhari et al. 2014; Mimche et al. 2012; Chung et al. 2012). Zhang et al. reported that curcumin could reduce the mRNA expression of LPS-induced CCL2 in the rat C6 astrocytoma cell line in a dose-dependent manner through inhibition of the JNK signaling pathway (Zhang et al. 2012). However, Herman and colleagues suggested that CCL2 activity could be inhibited via protein kinase C (PKC) and matrix metalloproteinases (MMP) (Herman et al. 2009). Liu et al. reported that curcumin inhibited ox-LDL-induced MCP-1 expression in macrophages via the NF- κ B and JNK pathways (Liu et al. 2014). Zhong et al. evaluated the effects of curcumin on LPS-induced MCP-1 production in the RAW264.7 macrophage cell line and demonstrated that curcumin reduced MCP-1 expression in a concentration-dependent manner. These authors showed that this effect

Table 1 Characteristics of chemokines and chemokine receptors

Name	Synonyms	Receptor	Target cell	Major function
<i>C family</i>				
XCL1	Lymphotactin α , SCM-1 α , ATAC	XCR1	T cell, NK, CD8 α^+ dendritic cell	T cell and NK recruitment
XCL2	Lymphotactin β , SCM-1 β	XCR1	T cell, NK, CD8 α^+ dendritic cell	Unknown
<i>CC family</i>				
CCL1	I-309, TCA3, P500, SISE, SCYA1	CCR8	Monocyte, neutrophil, T cell (Th2 > Th1)	Monocyte recruitment and endothelial cell migration
CCL2	MCP-1	CCR2	T cell (Th2 > Th1), monocyte, basophil, immature dendritic cell, NK	Mixed leukocyte recruitment
CCL3	MIP-1 α , LD78	CCR1, 5	Monocyte/macrophage, T cell (Th1 > Th2), NK, basophil, immature dendritic cell, eosinophil, neutrophil, astrocyte, fibroblast, osteoclast	Mixed leukocyte recruitment
CCL4	MIP-1 β	CCR1, 5	Monocyte/macrophage, T cell (Th1 > Th2), NK, basophil, immature dendritic cell, eosinophil, B cell	T cell, dendritic cell, monocyte and NK recruitment HIV co-receptor
CCL5	RANTES	CCR1, 3, 5	Monocyte/macrophage, T cell (memory T cell > T cell; Th1 > Th2), NK, basophil, eosinophil, immature dendritic cell	Mixed leukocyte recruitment
CCL6	C10, MRP-1, SCYA6	CCR1	Monocyte, B cell, CD4 $^+$ T cell, NK	Unknown
CCL7	MARC, MCP-3	CCR1, 2, 3, 5	Th2 > Th1 cell, monocyte, eosinophil, basophil, immature dendritic cell, NK	Mixed leukocyte recruitment
CCL8	MCP-2	CCR1, 2b, 5	Th2 > Th1 cell, monocyte, eosinophil, basophil, immature dendritic cell, NK	Mixed leukocyte recruitment
CCL11	Eotaxin	CCR3, 5	Eosinophil, basophil, mast cell, Th2 cell	Eosinophil, basophil and Th2 recruitment
CCL12	MCP-5	CCR2	Eosinophil, monocyte, T cell, B cell	Mixed leukocyte recruitment
CCL13	MCP-4, NCC-1, Ck β 6	CCR2, 3, 5	Th2 > Th1 cell, monocyte, eosinophil, basophil, dendritic cell	Mixed leukocyte recruitment
CCL14a	HCC-1	CCR1, 3, 5	Monocyte	Unknown
CCL14b	HCC-3	unknown	Monocyte	Unknown
CCL15	MIP-5, HCC-2	CCR1, 3	T cell, monocyte, eosinophil, dendritic cell	Mixed leukocyte recruitment
CCL16	HCC-4, LEC	CCR1, 2, 5, 8	Monocyte, T cell, NK, immature dendritic cell	Lymphocyte and monocyte recruitment
CCL17	TARC	CCR4, 8	Th2 > Th1 cell, immature dendritic cell, thymocytes, regulatory T cells	T cell recruitment
CCL18	DC-CK1, PARC	PITPNM3	Naïve T cell > activated T cell, immature dendritic cell, mantle zone B cell	Lymphocyte and dendritic cell homing
CCL19	MIP-3 β , ELC	CCR7	Naïve T cell, mature dendritic cell, B cell	T cell and dendritic cell migration into para-follicular zones of lymph nodes
CCL20	MIP-3 α , LARC	CCR6	Memory T cells, Th17 cells, blood mononuclear cells, immature dendritic cells, activated B cells, GALT development	Th17 recruitment Dendritic cell positioning in tissue
CCL21	SLC, 6CKine, Exodus-2, Ck β 9	CCR7	Naïve T cell, B cell, thymocyte, NK, mature dendritic cell	T cell and dendritic cell migration into para-follicular zones of lymph nodes
CCL22	MDC	CCR4	Immature dendritic cell, NK, T cells (Th2 > Th1), thymocyte, endothelial cell, monocyte, regulatory T cell	NK and T cell recruitment

Table 1 (continued)

Name	Synonyms	Receptor	Target cell	Major function
CCL23	MPIF-1, CK- β	CCR1, FPRL-1	Monocyte, T cell, resting neutrophil	Monocyte, neutrophil and T cell migration
CCL24	Eotaxin-2, MPIF-2, Ck β 6	CCR3	Eosinophil, basophil, T cell	Eosinophil, basophil and Th2 recruitment
CCL25	TECK	CCR9	Macrophage, thymocyte, dendritic cell, intraepithelial lymphocyte, IgA plasma cell, mucosal memory T cell	Lymphocyte recruitment into intestine
CCL26	Eotaxin-3, MIP-1 α , IMAC, TSC-1	CCR3	Eosinophil, basophil, fibroblast	Eosinophil, basophil and Th2 recruitment
CCL27	CTACK	CCR10	Skin homing memory T cell, B cell	T cell recruitment into skin
CCL28	MEC	CCR10	T cell, eosinophil, IgA ⁺ B cell	T and B cells homing in mucosa
CXC family				
CXCL1	GRO- α , GRO-1, NAP-3, KC	CXCR2	Neutrophil, fibroblast	Neutrophil recruitment
CXCL2	GRO- β , GRO-2, NAP-2 α	CXCR2	Neutrophil, fibroblast	Neutrophil recruitment
CXCL3	GRO- γ , GRO-1, NAP-3	CXCR2	Neutrophil, fibroblast	Neutrophil recruitment
CXCL4	PF4	CXCR3b	Fibroblast, endothelial cell	Platelet aggregation
CXCL5	ENA-78	CXCR2	Neutrophil, endothelial cell	Neutrophil recruitment
CXCL6	GCP-2	CXCR2	Neutrophil, endothelial cell	Neutrophil recruitment
CXCL7	NAP-2	CXCR1, 2	Fibroblast, neutrophil, endothelial cell	Neutrophil recruitment
CXCL8	IL-8, NPP-1, MDNCF, GCP-1	CXCR1, 2	Neutrophil, basophil, endothelial cell	Neutrophil recruitment
CXCL9	Mig, CRG-10	CXCR3	Activated T cell (Th1 > Th2), NK, B cell, endothelial cell, plasmacytoid dendritic cell	Effector T cell recruitment
CXCL10	IP-10, CRG-2	CXCR3	Activated T cell (Th1 > Th2), NK, B cell, endothelial cell	Effector T cell recruitment
CXCL11	IP-9, ITAC, β -R1	CXCR3	Activated T cell (Th1 > Th2), NK, B cell, endothelial cell	Effector T cell recruitment
CXCL12	SDF-1 α/β	CXCR4, 7	CD34 ⁺ bone marrow cells, thymocytes, monocytes/macrophages, naïve activated T cell, B cell, plasma cell, neutrophil, immature and mature dendritic cells, plasmacytoid dendritic cells	B cell migration into lymph nodes Plasma cell migration into bone marrow
CXCL13	BCA-1, BLC	CXCR5	Naïve B cell, activated CD4 T cells, immature and mature dendritic cells	B cell migration into lymph nodes and into follicles T follicular helper cell migration into follicles
CXCL14	BRAK, Bolekine	unknown	T cell, monocyte, B cell	Monocyte and dendritic cell migration
CXCL15	Lungkine, WECHÉ	unknown	Neutrophil, epithelial cell, endothelial cell	Unknown
CXCL16	Sexckine	CXCR6	Activated T cell, NKT, endothelial cells	Macrophage scavenger receptor
CX₃C family				
CX₃CL1	Fractalkine, Neurotactin, ABCD-3	CX₃CR1	Activated T cell, monocyte, neutrophil, NK, immature dendritic cell, mast cell, astrocytes, neurons, microglia	T cell, NK and macrophage recruitment

SCM-1 α single C motif-1 α , *ATAC* activation-induced T cell-derived and chemokine-related cytokine, *Th* helper T cell, *MCP-1* Monocyte chemoattractant protein-1, *MIP-1 α* Macrophage inflammatory protein-1 α , *HIV* human immunodeficiency virus, *RANTES* Regulated on Activation Normal T Cell Expressed and Secreted, *MCP-4* Monocyte chemoattractant protein-4, *HCC-1* hemofiltrate CC chemokine-1, *7ARC* T cell and activation-related chemokine, *ELC* Epstein-Barr virus-induced receptor ligand chemokine, *GALT* gastrointestinal-associated lymphoid tissue, *LARC* liver and activation-related chemokine, *SLC* secondary lymphoid tissue chemokine, *MDFC* macrophage-derived chemokine, *MPIF-1* myeloid progenitor inhibitory factor-1, *MPIF-2* myeloid progenitor inhibitory factor-2, *TECK* thymus-expressed chemokine, *NAP-3* neutrophil activation peptide-3, *KC* keratinocyte chemoattractant, *ENA-78* epithelial cell-derived neutrophil-activating factor-78 amino acids, *GCP-2* granulocyte chemoattractant protein-2, *Mig* monokine-induced by γ -interferon, *IP-10* γ -interferon-inducible protein 10, *SDF-1 α/β* stromal cell-derived factor, *BLC* B-lymphocyte chemokine




Fig. 1 Various molecular targets through which curcumin inhibits MCP-1

occurred due to upregulation in the expression of heme oxygenase-1 (HO-1), which inhibits the production of LPS-induced reactive oxygen species (ROS) (Zhong et al. 2013). Bao et al. reported that curcumin reduced LPS-induced MCP-1 expression in the fetus-derived glomerular mesangial cells (Bao et al. 2003). In addition, Tham and colleagues showed that curcumin could downregulate CCL2 expression in human umbilical vein endothelial cells (HUVEC) at concentrations lower than 12.5 μM after 24 h of exposure to curcumin (Tham et al. 2015). Moreover, Ziaei et al. reported that concentrations of curcumin lower than 12.5 μM were able to significantly inhibit TNF- α -induced expression of MCP-1 in HUVECs after 3 h of exposure (Ziaei et al. 2015). Meng et al. also showed that curcumin pre-treatment (3–50 $\mu\text{M/L}$) could attenuate the LPS-induced expression of MCP-1 in a dose-dependent manner in vascular smooth muscle cells (VSMCs) (Meng et al. 2013). These studies demonstrate the universal CCL2-inhibitory effects conferred by curcumin.

CXCR4/CXCL12

CXCR4 and its ligand, CXCL12, or stromal cell-derived factor-1 (SDF-1), are involved in the development of hematopoietic, endothelial, and nervous system tissues and regulate the migration, homing, and survival of progenitor cells

during embryogenesis. In addition, the CXCR4/CXCL12 axis plays a key role in HIV infection, stem cell mobilization, autoimmune disorders, cancers, and tissue regeneration (Shishodia 2013; Peled et al. 2012). Several studies have shown that curcumin induces CXCR4 expression in the follicular lymphoma cell line (Skommer et al. 2007) and mediates the migration of retinal endothelial cells in humans (Sameermahmood et al. 2008). In addition, curcumin has been shown to impair the expression of CXCL12 and decrease select proteins in human tumor cell lines. Interestingly, using an orthotropic mouse model, it has been demonstrated that curcumin-mediated inhibition of CXCL12 expression serves to sensitize colorectal cancer cells to capecitabine by modulating the expression of CXCR4 (Kunnumakkara et al. 2009).

CCR7/CCL21

Fu et al. conducted a study to evaluate the effects of curcumin on healthy human circulatory leukocyte-derived fibrocytes and reported that curcumin treatment (20 μM for 72 h) significantly reduced CCR7 expression (Fu et al. 2015). It appears that the differentiation and migration of human circulatory fibrocytes occurs via regulation of the CCR7/CCL21 axis, in particular, reduction in the expression of CCR7 (Sun et al. 2017).

Chemokine-based therapeutic effects of curcumin (Table 2)

Inflammatory diseases

Nervous system (Fig. 2)

Astrocytes are the most abundant glial cells in the central nervous system (CNS) and are involved with maintaining hemostasis and neuronal function (Röhl et al. 2007; Farina et al. 2007). Astrocytes influence the migration of immune cells across the blood–brain barrier (BBB) via MCP-1 expression (Ransohoff et al. 2003). Curcumin has been documented to significantly reduce the production of pro-inflammatory cytokines and chemokines, including MCP-1 and MIP-1 β , in astrocytes and microglial cells through the inhibition of JNK phosphorylation (Qureshi et al. 2018; Chen et al. 2015; Zhang et al. 2012). Seyedzadeh and colleagues evaluated the immunomodulatory effects of curcumin on the LPS-induced U373-MG human astrocyte cell line as an in vitro model of multiple sclerosis and demonstrated that curcumin could attenuate the expression of the MCP-1, which serves as the key chemoattractant for recruitment of immune cells into the CNS (Seyedzadeh et al. 2014). In

Table 2 Chemokine-based therapeutic effects of curcumin in experimental models

Inflam- matory diseases	Nervous system	In vitro models	Curcumin dose/concentration	Type of model	Findings	Ref
			0, 2.5 and 5 μ M	LPS-induced U373-MG human astrocyte cell line as a model of MS	The MCP-1 expression \downarrow	(Seyedzadeh et al. 2014)
			1, .5, 10, 15 and 20 μ M for 24 h	Mouse N9 microglial cells	HIV-1 gp120-induced expression of MCP-1 \downarrow	(Guo et al. 2013)
			10 and 25 μ M curcumin 30 min prior to LPS treatment	LPS-treated microglial cells and astrocytes	The LPS-induced expression of MCP-1 \downarrow	(Chen et al. 2015)
			40 mg/kg	Rat model of acute SCI LPS-challenged astrocytes	RANTES expression \downarrow	(M. S. Lin et al. 2011)
			100 mg/kg for 14 days	Rat model of sciatic nerve CCI	NF- κ B p65 and CX3CR1 in the spinal cord and DRG \downarrow CCI-induced neuropathic pain \downarrow	(H. Cao et al. 2014)
		In vivo models	100 mg/kg	PTZ-induced rat model of chronic epilepsy	Glial cell activation \downarrow MCP-1 expression in the hippocampus and cortex \downarrow Cognitive deficits \downarrow	(Kaur et al. 2015)
			20 mg/kg PLGA-encapsulated Cur-NPs	Mouse model of EBI after experimentally-induced SAH	The expression of MCP-1, MIP-2, and CINC-1 \downarrow	(Z. Y. Zhang et al. 2017)
			100 mg/kg	Both in vitro experiments and an in vivo rat model	The expression of MCP-1, CXCL10, and RANTES \downarrow Infiltration of T cells and macrophages \downarrow	(Yuan et al. 2017)
			50, 100 and 200 mg/kg for 10 days	Arthritic pain in a rat model of spinal cord inflammation	Glial scar formation \downarrow Inflammation-induced fibrosis \downarrow Activation of glial cells \downarrow Production of MCP-1 and MIP-1 α inflammatory mediators in the spinal cord \downarrow	(Chen et al. 2015)
			0.8 g/kg for 12 weeks	p25Tg transgenic mice as experimental animal model for AD	Neuro-inflammation and neurodegeneration \downarrow Production of MIP-1 α \downarrow	(Sundaram et al. 2017)
	Liver	In vivo models	100 mg/kg	Rat model of metabolic and chemical-induced NASH	CX3CL1 \uparrow RANTES \downarrow	(Pickich et al. 2019)
			200 mg/kg for 4 weeks	Mouse model of CCl ₄ -induced liver fibrosis (in vivo)	MCP-1 and CCL7 \downarrow Infiltration of Ly6C ^{high} monocytes in the liver \downarrow	(X. A. Zhao et al. 2018)
				RAW264.7 cells (in vitro)		

Table 2 (continued)

	Curcumin dose/concentration	Type of model	Findings	Ref
Cardiovascular disorders	200 mg/kg for 6 weeks	Rat model of CCl ₄ -induced liver fibrosis	MCP-1 expression ↓ Liver injuries ↓	(Tu et al. 2012)
	50 mg/kg for 8 weeks	Rat model of CCl ₄ -induced liver fibrosis	CXCL12/CXCR4 biological axis ↓ Hepatic stellate cell activation and migration ↓	(Qin et al. 2018)
	200 mg/kg	Murine model of ConA-induced hepatitis	CXCL10 ↓ Disease severity ↓	(Tu et al. 2011)
In vitro models	0.1, 1, 5 and 10 μM curcumin + 0.1, 0.5, 1 and 5 μM luteolin	TNF-α-induced vascular inflammation in EA.hy926 human endothelial cell line	MCP-1 expression ↓	(L. Zhang et al. 2019)
	combined curcumin (500 mg/kg) and luteolin (500 mg/kg) therapy for 1 week	Mouse aortic endothelial cells		
	Not mentioned	oxLDL-treated macrophages	MCP-1 expression ↓	(T. Liu et al. 2014)
Kidney diseases	1 and 5 mg/kg for 3 days	Murine renal cells (in vivo) Human HK-2 renal tubular epithelial cell line (in vitro)	MCP-1 and CXCL8 expression ↓	(F. Zhong et al. 2011)
	30 mg/kg over a 5-week period	Factor-H-deficient mice	MCP-1 expression ↓	(Jacob et al. 2013)
	100 mg/kg/day for 8 weeks	STZ-induced diabetic nephropathy rat model	Levels of inflammatory mediators (<i>i.e.</i> , MCP-1) ↓ Macrophage recruitment into the renal tissue ↓	(Soetikno et al. 2011)
Lungs	120 mg/kg for 5 days both as pre-treatment and post-treatment	Rat model of cisplatin-induced nephrotoxicity	Pre-treatment; the levels of the CXCL8 chemokine ↓ and inflammation and toxicity ↓ Post-treatment; no positive effects	(Kumar et al. 2017)
	100 mg/kg with/without cisplatin	Mice with cisplatin-induced nephrotoxicity	The expression of MCP-1 ↓	(Ueki et al. 2013)
	Not mentioned	Hydrogen peroxide-treated human A549 alveolar epithelial cells	IL-8 and ROS production ↓	(Biswas et al. 2005)
In vivo models	100 μM for 24 h	AEC II isolated from the rat model of COPD	IL-8, MCP-1, and MIP-2α inflammatory mediators ↓	(Gan et al. 2016)
	Not mentioned	BEAS-2B human bronchial epithelial cell line	Ovalbumin and IL-4-induced MCP-1 overexpression ↓	(Zhu et al. 2019)
	0.2, 0.5, 1 and 2% w/w for 7 days as pre-treatment	NTHI lysate exposed mice	KC expression in BALF ↓ Neutrophil recruitment to the lungs ↓	(Moghaddam et al. 2009)
	75, 150 and 300 mg/kg	Murine model of bleomycin-induced ALI	CXCL1, CXCL5 and CXCR12 in the lungs ↓	(Gouda and Bhandary 2018)

Table 2 (continued)

	Curcumin dose/concentration	Type of model	Findings	Ref
	Not mentioned	Mouse model of acute LPS-induced lung injury	MIP-2 in the BALF ↓	(J. Kim et al. 2016)
	50 mg/kg	Murine model of <i>staphylococcus aureus</i> -induced ALI	MCP-2 and KC levels ↓ Infiltration of neutrophils into lung tissue ↓	(Xu et al. 2015)
	50 mg/kg for 5 days as prophylaxis	mice with viral-induced ARDS	MCP-1 expression in both in inflammatory infiltrates and lung tissue ↓	(Avasarala et al. 2013)
	Not mentioned	Murine model of chronic asthma	Ovalbumin and IL-4-induced MCP-1 overexpression ↓	(Zhu et al. 2019)
	5 mg/kg	Mouse model of ovalbumin-induced chronic asthma	CCL11 expression ↓ Fibrosis ↓	(Chauhan et al. 2017)
	20 and 100 mg/kg	Mouse model of ovalbumin-induced allergic asthma	Eotaxin expression ↓	(Shahid et al. 2019)
Bowel diseases	In vitro models 50 µg/mL	CEC	Mucosal infiltration of neutrophils ↓ MIP-2, KC, and MIP-1α expression and secretion ↓	(Larmonier et al. 2011)
	50 µM	T-84 human colorectal carcinoma cells and young adult mouse colonocytes (YAMC)	The colonic expression of CXCL9, CXCL10, and CXCL11 ↓	(Midura-Kiela et al. 2012)
	In vivo models 0.2% w/w nanoparticle curcumin 7 days before model induction	DSS-induced murine model of experimental colitis	Mucosal expression of CXCR1 and CXCR2 ↓	(Ohno et al. 2017)
Joints	In vitro models 1–20 µM liposomal curcumin (Lipocurc™)	SW982 human synovial fibroblast and RAW264 murine macrophage cell line	The expression of inflammatory chemokines ↓	(Kloesch et al. 2016)
	3 µM; pre-treatment for 30 min	human OASFs	The MCP-1-induced VCAM-1 expression ↓	(Y. M. Lin et al. 2012)
Others	In vivo models 0.3 and 1 µM curcumin and its analog, CUR-Br before induction	TPA-induced ear edema murine mode (in vivo)	KC/CXCL1 ↓	(Rakariyatham et al. 2019)
	10 µM	Murine model of RP (in vivo)	Progression of retinal degeneration ↓ Activation of microglia cells ↓ following the CCL2 expression inhibition	(Y. Wang et al. 2017b)
	6, 30 and 60 µg/kg	New Zealand white rabbits (in vivo)	Improved the wound healing process via the significant ↓ in IL-1, IL-6, and IL-8	(Jia et al. 2014)
	50 µM	LPS-stimulated neutrophils (in vitro)	Neutrophil infiltration ↓ MIP-1α, MIP-1β, IL-8, and GRO-α expression ↓	(Antoine et al. 2013)

Table 2 (continued)

	Curcumin dose/concentration	Type of model	Findings	Ref
Infectious diseases		Murine model of air pouch inflammation (in vivo)		
	In vitro models	Not mentioned	CXCL5 expression ↓	(Konduru et al. 2016)
Bacterial infections		HMEECs		
		200 μM for 5 to 60 min	The release of IL-8 and MCP-1 ↓	(Lüer et al. 2012)
		Live <i>Moraxella catarrhalis</i> bacteria-exposed Detroit 562 pharyngeal cell line as in vitro model of mucositis		
	In vivo models	500 mg/kg for 6 and 18 weeks	CCL20, CCL5, CXCL1, CXCL10, CXCL11, and CCL25 expression ↓	(Santos et al. 2015)
		50 mg/kg for 1 h before and 1 h after induction	CXCL5 expression ↓	(Konduru et al. 2016)
		PLGA-encapsulated curcumin	Severity of HSV-2 infection and risk for HIV ↓ The production of MCP-1 and other inflammatory mediators ↓	(Vitali et al. 2020)
Viral infections		HSV-2-infected mice		
	In vivo models	Pre-treatment with 5 or 50 μM	CXCL8, RANTES, and IP-10 expression ↓	(Ferreira et al. 2015)
Cancer		Human PC3 prostate cancer cell line		
	In vitro models	30 μM	Adhesion, invasion and motility ↓ CCL2 activity ↓	(Herman et al. 2009)
		25 μM	CXCL1 and CXCL2 expression ↓	(Kronski et al. 2014)
		15 μM		
		Human PC3 prostate cancer cell line	CXCL1 and CXCL2 expression ↓	(Killian et al. 2012)
		Oxaliplatin and curcumin	CXCL1 expression ↓	(Ruiz de Porras et al. 2016)
		5–40 μM for 24 h	NKD2-Wnt-CXCR4 signaling pathway ↓	(Z. Zhang et al. 2016)
		10, 25 and 50 μM for 24, 48 and 72 h	CXCL12 and CXCR4 expression ↓	(Xiaoling et al. 2010)
	In vivo models	Curcuminoids formulated for 8 weeks	Serum levels of MCP-1 ↓	(Panahi et al. 2014a)
		500 mg, three times a day for 4 weeks	MCP-1 ↓	(Panahi et al. 2015b)
Colorectal cancer patients		FOLFOX + 2 g/day curcumin		
		50 mg/kg for 4 days	No significant changes in the serum levels of CXCL1 following treatment	(Howells et al. 2019)
Murine model of colon cancer				
			CXCL1 and CXCL2 expression ↓	(Sakai et al. 2016)

Table 2 (continued)

Curcumin dose/concentration	Type of model	Findings	Ref
Topical curcumin (2 µM) and ursolic acid combined therapy	Murine model of skin tumor	CXCL2 expression ↓	(Tremmel et al. 2019)
Curcumin gum formulation (30 min chewing and packing)	Human healthy volunteers	Serum CXCL1 levels ↓	(Boven et al. 2019)
Curcumae radix extract (CRE)	Murine model of breast cancer metastasis (MMTV-PyMT transgenic mice) (in vivo)	CCR7 expression ↓ Motility and cellular migration ↓	(Kaya et al. 2019)
500 mg capsule form of phy-tosomal curcumin (CCP)	MCF7 cells (in vitro) Murine model of GBM	MCP-1 expression in TAM ↑ Destruction of GBM cells ↑	(Mukherjee et al. 2018)
Pregnancy	In vivo models	LPS-induced adverse pregnancy outcomes in a mouse model	(J. Zhou et al. 2017)
0.36 mg/kg	LPS-induced pre-eclampsia in a rat model	MCP-1 expression ↓ Blood pressure ↓ Concentration of urinary proteins ↓	(Gong et al. 2016)
In vivo models	1, 5, 10, 20 and 40 µg/ml for 24, 48 and 72 h	EESC cells	(Chowdhury et al. 2019)

LPS lipopolysaccharide, *MS* multiple sclerosis, *PTZ* pentylenetetrazole, *PLGA* poly lactide-co-glycolide, *Cur-NPs* curcumin nanoparticles, *EBI* early brain injury, *SAH* subarachnoid hemorrhage, *CINC-1* chemokine-induced neutrophil chemoattractant-1, *CCI* chronic constrictive injury, *DRG* dorsal root ganglion, *SCI* spinal cord injury, *AD* Alzheimer's disease, *NASH* non-alcoholic steatohepatitis, *CCl₄* carbon tetrachloride, *ConA* Concanavalin A, *oxLDL* Oxidized low-density lipoprotein, *STZ* streptozotocin, *ROS* reactive oxygen species, *KC* keratinocyte chemoattractant, *BALF* broncho-alveolar lavage fluid, *COPD* Chronic obstructive pulmonary disease, *NTHi* typeable *Haemophilus influenzae*, *AEC II* alveolar epithelial cell type II, *ALI* acute lung injury, *ARDS* acute respiratory distress syndrome, *CEC* colonic epithelial cells, *DSS* dextran sodium sulfate, *YAMC* young adult mouse colonocytes, *OASF* osteoarthritis synovial fibroblasts, *CUR-Br* 7'-bromo-curcumin, *TPA* 12-O-tetradecanoylphorbol-13-acetate, *RP* retinitis pigmentosa, *H. pylori Helicobacter pylori*, *OM* otitis media, *HMEEC* human median ear epithelial cell, *HSV-2* herpes simplex virus-2, *HIV* human immunodeficiency virus, *GEC* gp-120- exposed genital epithelial cell, *FOLFOX* folinic acid/5-fluorouracil/oxaliplatin chemotherapy, *HNSCC* head and neck squamous cell carcinoma, *CRE* curcumae radix extract, *CCP* phytosomal curcumin, *GBM* glioblastoma, *TAM* tumor-associated macrophage and microglia, *EESC* eutopic endometrium-derived stromal cells




Fig. 2 Chemokine-based therapeutic effects of curcumin on nervous system

addition, Guo et al. reported that curcumin pre-treatment could attenuate the production of MCP-1 in the mouse N9 microglial cell line (Guo et al. 2013).

Following brain injury, microglial cells and astrocytes release inflammatory cytokines and chemokines that influence neuron survival and synaptic transmission, as well as increase brain excitability in epilepsy (Solito and Sastre 2012; Walker and Sills 2012; Vezzani et al. 2012). Kaur et al. evaluated the effects of curcumin on glial cell activation and the reduction in cognitive deficits in the pentylenetetrazole (PTZ)-induced rat model of chronic epilepsy and showed that 100 mg/kg of curcumin significantly inhibited glial cell activation. In addition, the expression of MCP-1 was reduced in the hippocampus and cortex with improved cognitive (Kaur et al. 2015). Furthermore, Zhang et al. evaluated the anti-inflammatory effects of poly (lactide-co-glycolide) (PLGA)-encapsulated curcumin nanoparticles (Cur-NPs) in subarachnoid hemorrhage-induced BBB disruption. Using a mouse model of early brain injury (EBI) after experimentally-induced subarachnoid hemorrhage (SAH), these authors demonstrated that the expression of inflammatory chemokines, including MCP-1, MIP-2, and

CINC-1 (chemokine-induced neutrophil chemoattractant-1), were significantly reduced following treatment with 20 mg/kg nano-curcumin suggesting that curcumin conferred protective effects in SAH (Zhang et al. 2017).

Spinal cord injury leads to glial scar formation by astrocytes, which severely hinders neuron regeneration. Using both in vitro experiments and an in vivo rat model, Yuan et al. reported that curcumin inhibits glial scar formation and inflammation-induced fibrosis. The authors demonstrated that curcumin downregulated the expression of MCP-1, CXCL10, and RANTES chemokines, as well as reduced the infiltration of T cells and macrophages by inhibiting NF- κ B signaling in astrocytes (Yuan et al. 2017).

Chen et al. evaluated the anti-inflammatory effects of curcumin on arthritic pain in a rat model of spinal cord inflammation and demonstrated that oral treatment with curcumin attenuated both the activation of glial cells and the production of MCP-1 and MIP-1 α inflammatory mediators in the spinal cord. Additionally, it was shown by these authors that the LPS-induced expression of MCP-1 was significantly reduced in cultured microglial cells and astrocytes (Chen et al. 2015). In another study using an experimental rat

model, Cao and colleagues evaluated the effects of curcumin on pain threshold and NF- κ B and CX3CR1 expression following sciatic nerve chronic constrictive injury (CCI). Cao et al. reported that curcumin significantly reduced the elevated expression of NF- κ B p65 and CX3CR1 in the spinal cord and dorsal root ganglion (DRG) and alleviated CCI-induced neuropathic pain (Cao et al. 2014). In another study, Lin et al. showed that curcumin reduced the expression of RANTES both in a rat model of acute spinal cord injury (SCI) and LPS-challenged astrocytes in vitro (Lin et al. 2011).

To evaluate the therapeutic effects of curcumin on neuroinflammation and neurodegeneration in Alzheimer's disease (AD), Sundaram et al. treated p25Tg transgenic mice (which overexpress p25 and act as an experimental animal model for AD) and demonstrated that curcumin efficiently counteracts glial cell activation and the production of inflammatory cytokines and chemokines such as MIP-1 α . These authors convincingly demonstrated that curcumin inhibited p25-mediated neuroinflammation and the progression of neurodegeneration in this experimental animal model of AD (Sundaram et al. 2017).

Th17 lymphocytes can migrate across the BBB and induce the recruitment of immune cells, which leads to inflammation in the CNS (Xie et al. 2011; Kebir et al. 2007). IL-17, the major cytokine secreted by Th17 cells, induces the production of CXCL1, CXCL2, and CXCL8/IL-8 chemokines and their receptors (*i.e.*, CXCR1 and CXCR2). These chemokines and their receptors are involved in the recruitment of lymphocytes and monocytes from the circulation into the CNS and, therefore, have been suggested to play a critical role in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Additionally, CXCL8 is involved with the infiltration of neutrophils (Carlson et al. 2008). Using the well-established EAE animal model, curcumin treatment was shown to decrease the recruitment and differentiation of inflammatory cells, especially Th17, in the CNS (Xie et al. 2009; Natarajan and Bright 2002). It would appear that these inhibitory functions result from the downregulation of NF κ B and disruption of CXCL1 and CXCL2 signaling pathways (Bachmeier et al. 2008; Choi et al. 2010).

Liver

Potential antioxidant, anti-inflammatory, and antifibrogenic effects of curcumin have been suggested to account for its beneficial hepatoprotective properties (Ghosh et al. 2011). All of these effects result from the pleiotropic and multi-target activity of curcumin. Accordingly, the numerous effects of curcumin on multiple organs and signaling pathways serve to regulate a wide variety of biochemical processes and influence the expression of different genes involved in

liver health and homeostasis (Vera-Ramirez et al. 2013). We now present multiple lines of evidence that highlight the hepatoprotective effects of curcumin via chemokine-dependent processes.

Pickich et al. evaluated the effects of curcumin on the serum levels of cytokines and chemokines in a rat model of metabolic (*i.e.*, Western diet (WD)) and chemical (*i.e.*, carbon tetrachloride (CCl₄))-induced non-alcoholic steatohepatitis (NASH). They reported that curcumin treatment resulted in a 121% increase in Fractalkine (or CX3CL1, which may have an anti-inflammatory and anti-fibrotic role in the liver) (The levels of RANTES or CCL5 that has increased expression in hepatocytes in both toxic and diet-induced liver injury and is associated with the pathogenesis and progression of non-alcoholic fatty liver disease was decreased by 22% Kirovski et al. 2010; Seki et al. 2009).

Ly6C^{high} monocytes facilitate liver fibrosis by inducing the production of pro-inflammatory and pro-fibrotic cytokines and chemokines (Pellicoro et al. 2014). MCP-1 and CCL7 are major players in the recruitment and migration of Ly6C^{high} monocytes (Brempeles and Crispe 2016). Zhao et al. reported that the mRNA expression of both MCP-1 and CCL7 was dramatically increased in a mouse model of CCl₄-induced liver fibrosis and that treatment with curcumin significantly reduced the expression of these inflammatory chemokines and decreased the infiltration of Ly6C^{high} monocytes in the liver. Moreover, these same authors noted that RAW264.7 cells co-cultured with curcumin resulted in a significant decrease in the expression of MCP-1 and CCL7. Interestingly, macrophages were induced to the M1 phenotype in a dose-dependent manner (Zhao et al. 2018). In another study, Tu et al. demonstrated that curcumin treatment (200 mg/kg for 6 weeks) in a rat model of CCl₄-induced liver fibrosis significantly reduced liver injuries due to MCP-1 and the inhibition of other mediators of inflammation (Tu et al. 2012).

It has been reported that curcumin influences various chemokines and exerts protective effects in the liver. Qin et al. reported the anti-fibrotic effects of curcumin in liver fibrosis via a dose-dependent inhibition of the CXCL12/CXCR4 biological axis, which leads to blockage of hepatic stellate cell activation and migration (Qin et al. 2018). Furthermore, using a murine model of Concanavalin A (ConA)-induced hepatitis, Tu et al. demonstrated that pre-treatment with 200 mg/kg curcumin reduced the levels of inflammatory mediators, including the CXCL10 chemokine, and alleviated disease severity (Tu et al. 2011).

Cardiovascular disorders

The cardiovascular protective effects of curcumin have been demonstrated in recent studies. Curcumin has previously been shown to ameliorate cardiac fibrosis, atherosclerosis,

and myocardial ischemia and infarction, as well as provide anti-inflammatory, antioxidant, and anti-apoptotic properties in various cardiovascular-related disorders (Pourbagher-Shahri et al. 2021; Li et al. 2020). There is an association between cardiovascular disease (CVD) and secreted cytokines, which serve as biomarkers of primary-phase inflammation (Karimian et al. 2017b). In other words, elevated chronic inflammation plays a key role in the development and progression of CVD (Ruparelia et al. 2017). Increased levels of inflammatory mediators lead to the simultaneous activation and adhesion of monocytes to the endothelium and the uptake of oxidized low-density lipoproteins (oxLDL). These processes facilitate the migration of monocytes to the sub-endothelial space and induce the proliferation of smooth muscle and foam cells and, subsequently, the formation of plaque (Ganjali et al. 2017a). MCP-1 and CXCL8/IL-8 chemokines are considered essential mediators in these events. Zhang et al. evaluated the effects of combined curcumin and luteolin therapy on the synergistic inhibition of TNF- α -induced vascular inflammation in human and mouse vascular cells. They reported that MCP-1 expression was significantly reduced in human endothelial cells with umbilical vein endothelial cell properties and mouse aortic endothelial cells. They showed that this effect resulted from the inhibition of NF- κ B translocation to the nucleus (Zhang et al. 2019). Additionally, Liu et al. reported that curcumin significantly reduced MCP-1 expression in oxLDL-treated macrophages by inhibiting the JNK and NF- κ B pathways, which suggests that the vascular protective effects of curcumin are related to anti-inflammation


and anti-atherosclerosis (Liu et al. 2014). Hence, it would appear that preparing drug formulations of curcumin that overcome obstacles such as low oral absorption and rapid metabolism might suggest its use for the treatment of CVD and CVD-associated disorders via a chemokine-dependent mechanism of action.

Kidney diseases

Different kidney disorders are often characterized by significant metabolic and nutritional disruptions that lead to oxidative stress, as well as uncontrolled and chronic inflammatory responses (de Almeida Alvarenga et al. 2018). Hence, curcumin has been proposed as an important nutritional adjuvant and therapeutic agent for various kidney-associated disorders, since it targets several signaling pathways important to kidney function.

As previously discussed, MCP-1 is essential for monocyte/macrophage infiltration and may play an important role in the development of tubulointerstitial fibrosis (TIF). Blocking the MCP-1/CCR2 pathway can inhibit the progression of fibrosis via the reduction in the recruitment of M1 macrophages (Wada et al. 2004; Kitagawa et al. 2004). In the rat model of unilateral ureteral obstruction (UUO), subcutaneous administration of curcumin significantly attenuated the overexpression of MCP-1 mRNA in the obstructed kidney (Jones et al. 2000). In a model of LPS-induced nephritis, the therapeutic effects of curcumin were mediated by the inhibition of MCP-1 expression and a decrease in monocyte recruitment. Zhong et al. reported that curcumin could

Fig. 3 Chemokine-based anti-inflammatory effects of curcumin in COPD



efficiently reduce LPS-induced mRNA overexpression of MCP-1 in both murine renal cells and the HK-2 renal tubular epithelial cell line. These same authors further reported that curcumin partially controlled the secretion of MCP-1 and CXCL8 chemokines (Zhong et al. 2011). Similar downregulation of MCP-1 levels has also been reported in factor-H-deficient mice resulting from the intraperitoneal administration of curcumin (30 mg/kg) over a 5-week period (Jacob et al. 2013).

Soetinko and colleagues evaluated the effects of 100 mg/kg/day of curcumin for 8 weeks in the streptozotocin (STZ)-induced diabetic nephropathy rat model. These authors demonstrated that curcumin dramatically reduced the levels of inflammatory mediators (*i.e.*, MCP-1) and macrophage recruitment into the renal tissue of diabetic mice. Macrophage infiltration into glomeruli leads to progressive glomerular injury and ultimately results in tubular and glomerular destruction (Soetikno et al. 2011). Similar results have been reported for a couple of curcumin derivatives (B06 and C66), which effectively reduced plasma levels of TNF- α and MCP-1 and improved renal fibrosis, histological abnormalities, and dysfunction in STZ-induced diabetic mice (Adhikary et al. 2004; Pan et al. 2013b).

Cisplatin is a chemotherapy agent for various types of cancers, and several reports have shown that high doses lead to nephrotoxicity in about 20% of patients (Yao et al. 2007). Kumar et al. evaluated the protective effects of curcumin both as pre-treatment and post-treatment in a rat model of cisplatin-induced nephrotoxicity. They reported that curcumin pre-treatment significantly reduced levels of the CXCL8 chemokine, as well as other inflammatory mediators, and attenuated inflammation and toxicity, while curcumin post-treatment showed no positive effects (Kumar et al. 2017). In another study using the same mouse model of cisplatin-induced nephrotoxicity, Ueki and colleagues reported that curcumin treatment dramatically reduced the expression of MCP-1 and other mediators in the kidney (Ueki et al. 2013).

Lungs

Chronic obstructive pulmonary disease (COPD) is associated with bronchial damage due to injury to both the epithelial and endothelial cell layers. Elevated levels of CXCL2 and IL-8 chemokines have been reported with COPD, which induce neutrophil recruitment to the lung parenchyma and the production of both proteinases and elastases (Lelli et al. 2017; Overbeek et al. 2013; Kobayashi and DeLeo 2009). It has been shown that in hydrogen peroxide-treated human A549 alveolar epithelial cells, curcumin decreased IL-8 and the production of reactive oxygen species (ROS) (Biswas et al. 2005). Additionally, curcumin significantly reduced the levels of the keratinocyte chemoattractant (KC)

chemokine (which is a murine homologue/homolog for human IL-8) in broncho-alveolar lavage fluid (BALF), and also led to the inhibition of neutrophil recruitment to the lungs (Moghaddam et al. 2009).

Using an experimental rat model of COPD, Gan et al. reported that the expression of inflammatory mediators, including IL-8, MCP-1, and MIP-2 α , were upregulated in alveolar epithelial cells type-II (AEC-II), and that the expression of histone deacetylase-2 (HDAC2) protein was significantly reduced. Following curcumin supplementation in this model, HDAC2 expression was restored, and H3/H4 acetylation and H3K9 methylation in the promoter region of the chemokines was decreased and increased, respectively, which led to a downregulation in the expression of the aforementioned inflammatory chemokines (Gan et al. 2016) (Fig. 3).

In another study, Gouda et al. investigated inflammatory pathways that are regulated by curcumin in a murine model of bleomycin-induced acute lung injury (ALI) and reported that the mRNA expression of CXCL1, CXCL5, and CXCR12 were significantly reduced in lung homogenates of curcumin-treated mice (Gouda and Bhandary 2018). Additionally, Kim and colleagues showed that curcumin dramatically reduced the expression of MIP-2 and other inflammatory mediators in the BAL fluid of mice with acute LPS-induced lung injury (Kim et al. 2016).

Xu et al. previously demonstrated that curcumin improved the respiratory condition in mice with *staphylococcus aureus*-induced ALI and reduced the levels of inflammatory cytokines and chemokines (e.g., MCP-2 and KC) but also decreased the infiltration of neutrophils into lung tissue (Xu et al. 2015). Additionally, Avasarala et al. have evaluated the anti-inflammatory and immunomodulatory effects of curcumin in mice with viral-induced acute respiratory distress syndrome (ARDS) and determined that curcumin prophylaxis (treatment) before the induction of inflammation significantly reduced the expression of inflammatory cytokines and chemokines (including MCP-1) in both inflammatory infiltrates and lung tissue (Avasarala et al. 2013).

Asthma is an inflammatory disorder that is characterized by pulmonary infiltration of eosinophils, neutrophils, and lymphocytes, as well as mucosal hypersecretion and airway hyper-responsiveness (AHR) (Elias et al. 2003). Importantly, MCP-1 (CCL2) is a critical inflammatory mediator in asthmatic airway epithelial cells (Hwang et al. 2017). Zhu et al. reported that curcumin significantly attenuated ovalbumin and IL-4-induced MCP-1 overexpression both in lung tissue of mice in a murine model of chronic asthma, as well as in the BEAS-2B cell line (human bronchial epithelial cells), and it appears that the inhibitory effects of curcumin were mediated by inactivation of the PPAR γ -dependent NF κ B signaling pathway (Zhu et al. 2019). Chauhan et al. evaluated the impact of intranasal curcumin on the inhibition of

pulmonary fibrosis in a mouse model of ovalbumin-induced chronic asthma and reported that curcumin dramatically reduced the expression of eotaxin (CCL11). CCL11 binds to its specific receptor, CCR3, on eosinophils, basophils, and mast cells and leads to the recruitment of these inflammatory cells to the airways. Moreover, CCL11/CCR3 interaction plays a vital role in the pathogenesis of asthma and airway remodeling and has pro-fibrotic effects on lungs and bronchial fibroblasts (Chauhan et al. 2017). Lastly, using the mouse model of ovalbumin-induced allergic asthma, Shahid et al. reported that curcumin significantly reduced the mRNA expression of inflammatory mediators such as eotaxin (Shahid et al. 2019).

Bowel diseases

In a very interesting *in vitro* study using colonic epithelial cells (CECs), it was shown that curcumin (50 µg/mL) decreased mucosal infiltration of neutrophils and significantly reduced the expression and secretion of MIP-2, KC, and MIP-1 α chemokines by neutrophils and CECs (Larmoirier et al. 2011). Along these lines, Ohno et al. reported that curcumin nanoparticles significantly reduced the mucosal mRNA expression of inflammatory cytokines and chemokines, including CXCR1 and CXCR2, in the dextran sodium sulfate (DSS)-induced murine model of experimental colitis. These same authors also reported that there was a dramatic decrease in the infiltration of Gr-1 neutrophils into the colon mucosa in the aforementioned model of experimental colitis (Ohno et al. 2017). Finally, Midura-Kiela and colleagues reported that curcumin decreased the colonic expression of CXCL9 (Mig), CXCL10 (IP-10), and CXCL11 (I-TAC), which are all CXCR3 ligands. All three chemokines are involved in epithelial dysfunction and the pathogenesis of inflammatory bowel disease (IBD). Specifically, these chemokines are secreted by colonic epithelial cells in an IFN- γ -induced manner and are a chemoattractant for activated T-lymphocytes and NK cells, although it should be noted that curcumin inhibits IFN- γ signaling (Midura-Kiela et al. 2012).

Osteoarthritis joints

Kloesch et al. reported that a liposomal curcumin formulation could significantly reduce the expression of inflammatory cytokines and chemokines both in SW982 human synovial fibroblast and RAW264 murine macrophage cell lines (Kloesch et al. 2016). Interestingly, Lin et al. have previously shown that in the synovial fluid of osteoarthritis (OA) patients, MCP-1 production is increased and that its interaction with CCR2 leads to enhanced VCAM-1 expression in osteoarthritis synovial fibroblasts (OASFs). This overall process of increased MCP-1 and elevated VCAM-1

expression is involved in the inflammatory process in synovial fibroblasts. This same group of authors also reported that a 30-min period of curcumin pre-treatment (3 µM) could inhibit the MCP-1-induced increase in VCAM-1 expression (Lin et al. 2012).

Other inflammatory diseases

Rakariyatham et al. have demonstrated that the curcumin analog, 7, 7'-Bromo-curcumin (CUR-Br), exhibits higher chemical stability and greater anti-inflammatory effects when compared to curcumin. Using the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced ear edema murine model, these same authors also reported that CUR-Br could more efficiently reduce the expression of inflammatory cytokines and chemokines, including KC/GRO (CXCL1), which is a key factor for the recruitment of neutrophils (Rakariyatham et al. 2019).

Wang et al. evaluated the therapeutic effects of curcumin in a murine model of retinitis pigmentosa (RP) in which retinal degeneration (rd1) occurs. Using this model, they showed that curcumin could effectively inhibit the expression of inflammatory mediators such as CCL2, as well as inhibit the activation of microglia cells and, as a result, slow the progression of retinal degeneration (Wang et al. 2017b).

In a study by Jia and colleagues, the effect of intravenously-administered curcumin was assessed for its role in wound healing in New Zealand white rabbits. They demonstrated that curcumin could improve the wound healing process by significantly reducing inflammatory cytokines and chemokines, including IL-1, IL-6, and IL-8 (Jia et al. 2014).

Lastly, Antoine et al. evaluated the anti-inflammatory effects of curcumin on neutrophil activation and infiltration and showed that the expression of MIP-1 α , MIP-1 β , IL-8, and GRO- α chemokines were reduced in LPS-stimulated neutrophils *in vitro*, whereas, in the well-established murine model of air pouch inflammation, curcumin significantly decreased the production of multiple inflammatory cytokines and chemokines, including MIP-1 α and MIP-1 β , as well as dramatically reduced neutrophil infiltration (Antoine et al. 2013).

Infectious diseases

Bacterial infection

Recently, a number of studies have investigated various antibacterial effects of curcumin. Suppressing bacterial DNA replication, inhibiting pathogen motility, and influencing the integrity of the microbial cell membrane are among the most important antibacterial mechanisms of action (Teow et al. 2016). In addition, curcumin administration has been shown




Fig. 4 Chemokine-based anti-tumor effects of curcumin

to affect the expression of specific microbial genes, such as *mecA* (Rai et al. 2008), as well as toxin binding activity (Na et al. 2011). In this review, we have focused on how curcumin affects both chemokine-related, as well as host-related protective mechanisms in the context of bacterial infections.

Curcumin has been suggested as a dietary supplement for preventing mucosal destruction associated with *Helicobacter pylori* (*H. pylori*) infection. Santos and colleagues evaluated the anti-inflammatory effects of curcumin on *H. pylori*-induced infection in an experimental mouse model and reported that curcumin significantly reduced the expression of pro-inflammatory mediators including CCL20, CCL5, CXCL1, CXCL10, CXCL11, and CCL25 in the infected mice (Santos et al. 2015).

In another study, Konduru et al. evaluated the therapeutic effects of curcumin on CXCL5 expression in both an in vivo murine model (non-typeable *Haemophilus influenzae* (NTHi)-induced otitis media (OM)) and an in vitro model using human median ear epithelial cells (HMEECs). These authors reported that NTHi-induced CXCL5 expression was significantly reduced via direct inhibition of IκK-β phosphorylation, together with inhibition of p38 MAPK (Konduru et al. 2016).

Lastly, Luer et al. evaluated the anti-inflammatory effects of curcumin on mucositis in an in vitro model. The Detroit 562 pharyngeal cell line was exposed to live *Moraxella catarrhalis* bacteria. These authors showed that treatment with curcumin (200 μM) for 5 to 60 min completely inhibited the release of inflammatory cytokines and chemokines, including IL-8 and MCP-1. Moreover, they determined that repetitive exposure to curcumin led to repetitive inhibition of these mediators for 4 to 6 h (Lüer et al. 2012).

Viral infection

In addition to the antifungal and antimicrobial properties of curcumin, recent studies have shown that curcumin also possesses antiviral activity against several infections caused by a virus (Jennings and Parks 2020). Therefore, below we present the chemokine-related antiviral effects of curcumin.

Herpes simplex virus-2 (HSV-2) is a common sexually transmitted virus that induces the recruitment of HIV-targeted immune cells and is considered a risk factor for human immunodeficiency virus (HIV) infection in female genital tracts. Vitali et al. reported that intravaginal (but not oral or intraperitoneal) delivery of curcumin nanoparticles to the

genital tract of mice could attenuate tissue inflammation and diminish the production of pro-inflammatory mediators, including TNF- α , IL-6, and MCP-1, and potentially lead to both a reduction in the severity of HSV-2 infection and decreased risk for HIV (Vitali et al. 2020).

In a different study, Ferreira and colleagues evaluated the anti-inflammatory potential of curcumin in genital epithelial cells (GECs) as a means to protect them from HIV-1 and HSV-2 viruses. These authors demonstrated that curcumin pre-treatment could restore the integrity of the mucosal barrier, along with inhibition of gp120-mediated upregulation of inflammatory cytokines and chemokines, which included CXCL8, RANTES, and IP-10. These are critical chemoattractants for recruiting HIV target cells to the female genital tract (FGT). Thus, it would appear that curcumin can inhibit and/or control virus proliferation in the FGT (Ferreira et al. 2015).

Cancer (Fig. 4)

Many different studies have documented the efficacy of curcumin as an adjunct chemotherapeutic agent for a variety of cancers. Some of these cancers include breast cancer, prostate cancer, squamous cell carcinoma of the head and neck, lung cancer, and brain tumors. The proposed mechanism of action underlying the beneficial effects of curcumin in various cancers is related to the induction of apoptosis and curcumin-mediated suppression of tumor cell proliferation and invasion. The therapeutic effects of curcumin in cancer occur through a variety of cell signaling pathways (Tomeh et al. 2019). Below, we describe and summarize different studies that have been conducted to evaluate the anticancer potential of curcumin as it pertains to the regulation of chemokines.

It has been previously reported that curcumin can inhibit lung metastasis in mice (Bachmeier et al. 2007). Another study reported that curcumin supplementation for 5 days following the removal of a primary mammary tumor in mice leads to a reduced incidence of metastasis to the lungs (Aggarwal et al. 2005). Interestingly, curcumin decreases both the expression of MCP-1 and IL-1 β inflammatory mediators, which are critical for tumorigenesis (Abe et al. 1999). Panahi et al. reported that curcuminoids formulated to have an increased bioavailability (since curcumin alone is poorly absorbed after oral administration) reduced the serum levels of MCP-1 in patients with solid tumors after 8 weeks of treatment (Panahi et al. 2014b). These same authors also determined that 500 mg curcumin, taken three times a day for 4 weeks, modulated the expression of MCP-1 in male patients with pulmonary complications arising from sulfur mustard intoxication (Panahi et al. 2015a).

In addition, in prostate cancer, CCL2 has an important role in the development of metastasis to the bone

(Bandyopadhyay 2014). Herman et al. reported that 30 μ M curcumin could downregulate CCL2 activity by inhibiting protein kinase C (PKC) and matrix metalloproteinase-9 (MMP-9) in human PC-3 and decreasing adhesion, invasion, and motility in a PC3 cell line in vitro (Herman et al. 2009).

Notably, curcumin can significantly regulate the gene expression of 62 genes in MDA-MB-231 breast cancer cells, and the genes for the pro-inflammatory chemokines CXCL1 and CXCL2 are among the genes that are most strongly downregulated (Bachmeier et al. 2008). Both chemokines have pivotal roles in the migration, proliferation, metastasis, and angiogenesis of tumor cells of various organs (Youngs et al. 1997; Loukinova et al. 2000). Kronski et al. reported that curcumin treatment of both MDA-MB-231 (human metastatic breast cancer cell line) and human primary mammary cancer-derived cells could downregulate the expression of CXCL1 and CXCL2 chemokines via downregulation of miR181b (Kronski et al. 2014). It was shown that miR181b modulation could influence tumor progression and metastasis (Bachmeier et al. 2018). Moreover, studies conducted with the prostate cancer metastasis model showed that curcumin could influence the CXCL1 and CXCL2 chemokines, induce apoptosis, inhibit proliferation, and modulate several metastasis-accelerating factors. In an independent study, Killian and colleagues reported that curcumin could inhibit NF κ B activation and reduce the expression of CXCL1 and CXCL2, which leads to the abolishment of the autocrine/paracrine loop between these two chemokines and NF κ B, as well as reduces the development of metastasis (Killian et al. 2012).

In breast cancer cells, it appears that after curcumin inhibits NF- κ B and the chemokines CXCL1 and CXCL2, the downregulation of CXCL1 leads to reduced expression of CXCR4 as a CXCL12/SDF-1 receptor. This overall process represents a metastasis-accelerating axis that could potentially serve as an avenue for therapeutic intervention (Bachmeier et al. 2008; Burger and Peled 2009). However, CXCL1 expression is limited to only a few types of breast cancer cells; however, it exists in the signature of metastasis to the lung (Albini et al. 2008; Minn et al. 2005). In addition, there is evidence that CXCL1 is associated with metastatic development of colorectal cancer, and tumors that highly express this chemokine have poor prognosis and survival (Wang et al. 2017a; Zhuo et al. 2018). Ruiz de Porras and colleagues have demonstrated that a cell culture of primary colorectal cancer cells with liver metastasis-derived cells had a high baseline expression of CXCL1 that was responsive to combination therapy employing oxaliplatin and curcumin, and these authors suggested that curcumin regulates the expression of CXCL1 via downregulation of NF- κ B (Ruiz de Porras et al. 2016). However, in a study by Howells et al., comparing the effects of FOLFOX (folinic acid/5-fluorouracil/oxaliplatin chemotherapy) and

CUFOX (FOLFOX + 2 g/day of oral curcumin) as therapeutic approaches in colorectal cancer patients, no significant differences were seen between plasma levels of CXCL1 before and after the intervention (Howells et al. 2019). 5-fluorouracil (5-FU) is a cancer chemotherapeutic agent that upregulates the expression of CXCL1 and CXCL2 in the bowel and also triggers neutrophil recruitment. Unfortunately, 5-FU treatment for colon cancer typically results in diarrhea. To this end, Sakai et al., using a murine model of colon cancer, reported that curcumin could inhibit 5-FU-mediated diarrhea by downregulating the expression of CXCL1 and CXCL2 in an NF κ B-dependent manner (Sakai et al. 2016).

Tremmel and colleagues evaluated the inhibitory effects of topical curcumin and ursolic acid on skin tumor progression and reported that this combination therapy could significantly reduce the expression of inflammatory cytokines and chemokines such as CXCL2. The combination therapy more efficiently abrogates tumor development compared to either agent used alone as monotherapy (Tremmel et al. 2019).

In head and neck squamous cell carcinoma associated with the oral cavity (HNSCC), Boven et al. evaluated the effects of a curcumin gum formulation as a means to prevent HNSCC associated with the oral cavity and showed that chewing and packing the gum against the buccal mucosa for 30 min in healthy volunteers could significantly reduce the serum levels of inflammatory mediators. Among the chemokines measured in this pilot study, which included CXCL1, IL-8, IP-10, and MIP-1 α , a significant reduction in serum CXCL1 levels was observed at 30 min and 4 h after chewing the curcumin gum (Boven et al. 2019).

Notably, CCR7 also plays a crucial role in metastasis and has emerged as a novel biomarker for metastasis to lymph nodes in breast cancer. Additionally, this chemokine receptor has been proposed as a prognostic indicator of metastasis in esophageal carcinoma (Legler et al. 2014; Cabioglu et al. 2005; Liu et al. 2013). Kaya et al. reported that curcumae radix extract (CRE) has anti-metastatic effects on MCF7 cells and in the murine model of breast cancer metastasis (MMTV-PyMT transgenic mice) and dramatically inhibits motility and cellular migration, as well as regulation in the gene expression of metastatic markers, including CCR7, metalloproteinase-9, and c-fus and c-jun proto-oncogenes (Kaya et al. 2019).

Downregulation of CXCR4 as a ‘metastasis-accelerating’ chemokine is another effect of curcumin on chemokines. It has been shown that CXCR4 is associated with tumor motility and invasion, and curcumin has been suggested for CXCR4-mediated inhibition of colorectal cancer progression (Zhang et al. 2016). Zhang et al. previously reported that curcumin inhibits the

NKD2-Wnt-CXCR4 signaling pathway in the SW620 colorectal cancer cell line and decreases tumor development (Zhang et al. 2016). In another study, Du et al. demonstrated that cancer-associated fibroblasts (CAFs) could induce epithelial-to-mesenchymal transition (EMT) in prostate cancer cells, as well as accelerate CXCR4 expression and invasion via the monoamine oxidase A/mammalian target of rapamycin (mTOR)/hypoxia-inducible factor-1 α (MAOA/mTOR/HIF-1 α) signaling pathway. Moreover, these same authors showed that curcumin abrogates invasion and CAF-induced EMT, as well as decreases ROS production and the expression of CXCR4 and IL-6R (Du et al. 2015). Finally, Xiaoling et al. reported that curcumin could dramatically inhibit the expression of CXCL12 and CXCR4, as well as invasion and motility potential, in the SKOV3 human ovarian cancer cell line in a dose-dependent manner (Xiaoling et al. 2010).

It has also been previously suggested that MCP-1 activates and induces M1 macrophages to produce IL-12, a natural killer (NK) cell activator. Thus, the release of MCP-1 in the brain could potentially recruit anti-tumor cells and activate anti-tumor responses. Mukherjee et al. reported that phytosomal curcumin (CCP) could significantly induce the expression of MCP-1 in tumor-associated macrophage and microglia (TAM) in a murine model of glioblastoma (GBM; a primary cerebral tumor) and facilitate the destruction of GBM cells (Mukherjee et al. 2018).

Adverse pregnancy outcomes

Zhou et al. reported that curcumin could ameliorate LPS-induced adverse pregnancy outcomes in a mouse pregnancy model by (1) upregulating Akt phosphorylation in the placenta, (2) reducing the expression of chemokines, such as macrophage migration inhibitory factor (MIF), MCP-1, and MIP-1, and (3) inhibiting the recruitment of CD86⁺ macrophages to the placenta (Zhou et al. 2017). In another independent study, pregnant rats received LPS to induce pre-eclampsia and then received treatment with curcumin. This study showed that curcumin could reduce blood pressure and the concentration of urinary proteins, as well as reduce the expression of inflammatory mediators such as TLR4, NF κ B, IL-6, and MCP-1 (Gong et al. 2016).

Lastly, Chowdhury and colleagues evaluated the effects of curcumin on the secretion of pro-inflammatory and pro-angiogenic cytokines and chemokines in cell culture of eutopic endometrium-derived stromal cells (EESC) in comparison to normal endometrial stromal cells (NESC). They demonstrated that curcumin significantly reduced the expression of inflammatory cytokines and chemokines, such as MCP-1 and RANTES, in a dose- and duration-dependent manner (Chowdhury et al. 2019).

Conclusion

The regulatory and anti-inflammatory effects of curcumin are well established, and it exerts its pharmacological effects through various molecular targets. In general, the biological effects of curcumin are broadly thought to be achieved by inhibition of NF- κ B, although, more specifically, the actual anti-inflammatory effects of curcumin are primarily mediated by downregulation in the activity COX-2, LOX, and iNOS. The present review article discussed the effects of curcumin on chemokines and chemokine receptors both in in vitro studies and in vivo experimental animal models of different pathologies that included inflammation in various organs, autoimmune diseases, cancer, and bacterial and viral infections. The findings of these studies have shown that curcumin can exert its inhibitory effects on chemokines, which generally function as pro-inflammatory mediators and are responsible for the recruitment of immune cells to sites of inflammation. As it relates to the neuroprotective effects provided to neuroglia and neurons, curcumin modulates the expression of different chemokines and reduces degeneration, injuries, and deficits associated with these cells' neuroinflammation.

Moreover, the inhibitory effect of curcumin on hepatic, cardiovascular, pulmonary, and renal inflammatory conditions results in decreased fibrosis and other inflammation-associated histological complications. Lastly, in the case of cancer, curcumin can inhibit chemokine expression, leading to inhibition of tumor metastasis and activating specific chemokines that recruit anti-tumor immune cells to the tumor microenvironment. However, clinical trials to treat these various disease states/pathologic disorders with curcumin in humans are limited. Thus, we would suggest that additional clinical studies evaluating curcumin use in humans are needed to reach unequivocal conclusions about the therapeutic effects of curcumin on these various disorders/disease states.

Acknowledgements None

Authors' contributions Not applicable.

Funding None.

Availability of data and material The data are available upon request.

Declarations

Competing interests Muhammed Majeed is the founder of Sami-Sabinsa group of companies.

Ethics approval Not applicable.

Consent for publication Not applicable.

References

- Abe Y, Hashimoto S, Horie T (1999) Curcumin inhibition of inflammatory cytokine production by human peripheral blood monocytes and alveolar macrophages. *Pharmacol Res* 39(1):41–47. <https://doi.org/10.1006/phrs.1998.0404>
- Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C, Dowling J, Atkins RC et al (2004) Abnormal p38 mitogen-activated protein kinase signalling in human and experimental diabetic nephropathy. *Diabetologia* 47(7):1210–1222. <https://doi.org/10.1007/s00125-004-1437-0>
- Aggarwal BB, Shishodia S, Takada Y, Banerjee S, Newman RA, Bueso-Ramos CE et al (2005) Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. *Clin Cancer Res* 11(20):7490–7498. <https://doi.org/10.1158/1078-0432.ccr-05-1192>
- Albini A, Mirisola V, Pfeffer U (2008) Metastasis signatures: genes regulating tumor-microenvironment interactions predict metastatic behavior. *Cancer Metastasis Rev* 27(1):75–83. <https://doi.org/10.1007/s10555-007-9111-x>
- Alidadi M, Jamialahmadi T, Cicero AFG, Bianconi V, Pirro M, Banach M et al (2020) The potential role of plant-derived natural products in improving arterial stiffness: a review of dietary intervention studies (Review). *Trends Food Sci Technol* 99:426–440. <https://doi.org/10.1016/j.tifs.2020.03.026>
- Antoine F, Simard JC, Girard D (2013) Curcumin inhibits agent-induced human neutrophil functions in vitro and lipopolysaccharide-induced neutrophilic infiltration in vivo. *Int Immunopharmacol* 17(4):1101–1107. <https://doi.org/10.1016/j.intimp.2013.09.024>
- Avasarala S, Zhang F, Liu G, Wang R, London SD, London L (2013) Curcumin modulates the inflammatory response and inhibits subsequent fibrosis in a mouse model of viral-induced acute respiratory distress syndrome. *PLoS ONE* 8(2):e57285. <https://doi.org/10.1371/journal.pone.0057285>
- Bachmeier B, Nerlich AG, Iancu CM, Cilli M, Schleicher E, Vené R et al (2007) The chemopreventive polyphenol Curcumin prevents hematogenous breast cancer metastases in immunodeficient mice. *Cell Physiol Biochem* 19(1–4):137–152. <https://doi.org/10.1159/000099202>
- Bachmeier BE, Mohrenz IV, Mirisola V, Schleicher E, Romeo F, Höhneke C et al (2008) Curcumin downregulates the inflammatory cytokines CXCL1 and -2 in breast cancer cells via NFkappaB. *Carcinogenesis* 29(4):779–789. <https://doi.org/10.1093/carcin/bgm248>
- Bachmeier BE, Killian PH, Melchart D (2018) The role of curcumin in prevention and management of metastatic disease. *Int J Mol Sci*. <https://doi.org/10.3390/ijms19061716>
- Bahrami A, Majeed M, Sahebkar A (2019) Curcumin: a potent agent to reverse epithelial-to-mesenchymal transition. *Cell Oncol* 2:1–17
- Bandyopadhyay D (2014) Farmer to pharmacist: curcumin as an anti-invasive and antimetastatic agent for the treatment of cancer. *Front Chem* 2:113. <https://doi.org/10.3389/fchem.2014.00113>
- Bao HY, Chen RH, Huang SM, Pan XQ, Fei L (2003) Curcumin inhibited the proliferation and extracellular matrix production of human mesangial cells. *Zhonghua Er Ke Za Zhi* 41(11):822–826
- Bavarsad K, Barreto GE, Hadjzadeh MAR, Sahebkar A (2019) Protective effects of curcumin against ischemia-reperfusion injury in the nervous system (review). *Mol Neurobiol* 56(2):1391–1404. <https://doi.org/10.1007/s12035-018-1169-7>
- Biswas SK, McClure D, Jimenez LA, Megson IL, Rahman I (2005) Curcumin induces glutathione biosynthesis and inhibits NF-kappaB activation and interleukin-8 release in alveolar epithelial cells: mechanism of free radical scavenging activity. *Antioxid*

- Redox Signal 7(1–2):32–41. <https://doi.org/10.1089/ars.2005.7.32>
- Bodnar RJ (2015) Chemokine regulation of angiogenesis during wound healing. *Adv Wound Care* 4(11):641–650
- Boven L, Holmes SP, Latimer B, McMartin K, Ma X, Moore-Medlin T et al (2019) Curcumin gum formulation for prevention of oral cavity head and neck squamous cell carcinoma. *Laryngoscope* 129(7):1597–1603. <https://doi.org/10.1002/lary.27542>
- Brempeles KJ, Crispe IN (2016) Infiltrating monocytes in liver injury and repair. *Clin Transl Immunol* 5(11):e113. <https://doi.org/10.1038/cti.2016.62>
- Bukhari SN, Lauro G, Jantan I, Bifulco G, Amjad MW (2014) Pharmacological evaluation and docking studies of α , β -unsaturated carbonyl based synthetic compounds as inhibitors of secretory phospholipase A₂, cyclooxygenases, lipoxygenase and proinflammatory cytokines. *Bioorg Med Chem* 22(15):4151–4161. <https://doi.org/10.1016/j.bmc.2014.05.052>
- Burger JA, Peled A (2009) CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. *Leukemia* 23(1):43–52. <https://doi.org/10.1038/leu.2008.299>
- Cabioglu N, Yazici MS, Arun B, Broglio KR, Hortobagyi GN, Price JE et al (2005) CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. *Clin Cancer Res* 11(16):5686–5693. <https://doi.org/10.1158/1078-0432.ccr-05-0014>
- Cabrero Heras S, Martínez-Balibrea E (2018) CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer. *World J Gastroenterol* 24(42):4738
- Cao H, Zheng JW, Li JJ, Meng B, Li J, Ge RS (2014) Effects of curcumin on pain threshold and on the expression of nuclear factor κ B and CX3C receptor 1 after sciatic nerve chronic constrictive injury in rats. *Chin J Integr Med* 20(11):850–856. <https://doi.org/10.1007/s11655-013-1549-9>
- Cao F, Liu T, Xu Y, Xu D, Feng S (2015) Curcumin inhibits cell proliferation and promotes apoptosis in human osteoclastoma cell through MMP-9, NF- κ B and JNK signaling pathways. *Int J Clin Exp Pathol* 8(6):6037–6045
- Carlson T, Kroenke M, Rao P, Lane TE, Segal B (2008) The Th17-ELR+ CXC chemokine pathway is essential for the development of central nervous system autoimmune disease. *J Exp Med* 205(4):811–823. <https://doi.org/10.1084/jem.20072404>
- Chauhan PS, Dash D, Singh R (2017) Intranasal curcumin inhibits pulmonary fibrosis by modulating matrix metalloproteinase-9 (MMP-9) in ovalbumin-induced chronic asthma. *Inflammation* 40(1):248–258. <https://doi.org/10.1007/s10753-016-0475-3>
- Chen JJ, Dai L, Zhao LX, Zhu X, Cao S, Gao YJ (2015) Intrathecal curcumin attenuates pain hypersensitivity and decreases spinal neuroinflammation in rat model of monoarthritis. *Sci Rep* 5:10278. <https://doi.org/10.1038/srep10278>
- Choi KH, Park JW, Kim HY, Kim YH, Kim SM, Son YH et al (2010) Cellular factors involved in CXCL8 expression induced by glycated serum albumin in vascular smooth muscle cells. *Atherosclerosis* 209(1):58–65. <https://doi.org/10.1016/j.atherosclerosis.2009.08.030>
- Chowdhury I, Banerjee S, Driss A, Xu W, Mehrabi S, Nezhat C et al (2019) Curcumin attenuates proangiogenic and proinflammatory factors in human eutopic endometrial stromal cells through the NF- κ B signaling pathway. *J Cell Physiol* 234(5):6298–6312. <https://doi.org/10.1002/jcp.27360>
- Chung SH, Choi SH, Choi JA, Chuck RS, Joo CK (2012) Curcumin suppresses ovalbumin-induced allergic conjunctivitis. *Mol vis* 18:1966–1972
- de Almeida Alvarenga L, de Oliveira Leal V, Borges NA, de Aguiar AS, Faxén-Irving G, Stenvinkel P et al (2018) Curcumin-A promising nutritional strategy for chronic kidney disease patients. *J Funct Foods* 40:715–721
- Deshmane SL, Kremlev S, Amini S, Sawaya BE (2009) Monocyte chemoattractant protein-1 (MCP-1): an overview. *J Interferon Cytokine Res* 29(6):313–326
- Du Y, Long Q, Zhang L, Shi Y, Liu X, Li X et al (2015) Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1 α signaling. *Int J Oncol* 47(6):2064–2072. <https://doi.org/10.3892/ijo.2015.3202>
- Elias JA, Lee CG, Zheng T, Ma B, Homer RJ, Zhu Z (2003) New insights into the pathogenesis of asthma. *J Clin Invest* 111(3):291–297. <https://doi.org/10.1172/jci17748>
- Esatbeyoglu T, Huebbe P, Ernst IM, Chin D, Wagner AE, Rimbach G (2012) Curcumin—from molecule to biological function. *Angew Chem Int Ed Engl* 51(22):5308–5332. <https://doi.org/10.1002/anie.201107724>
- Farina C, Aloisi F, Meinl E (2007) Astrocytes are active players in cerebral innate immunity. *Trends Immunol* 28(3):138–145. <https://doi.org/10.1016/j.it.2007.01.005>
- Ferreira VH, Nazli A, Dizzell SE, Mueller K, Kaushic C (2015) The anti-inflammatory activity of curcumin protects the genital mucosal epithelial barrier from disruption and blocks replication of HIV-1 and HSV-2. *PLoS ONE* 10(4):e0124903. <https://doi.org/10.1371/journal.pone.0124903>
- Fu XY, Zhang DW, Li YD, Zhao PW, Tang YQ, Niu JZ et al (2015) Curcumin treatment suppresses CCR7 expression and the differentiation and migration of human circulating fibrocytes. *Cell Physiol Biochem* 35(2):489–498. <https://doi.org/10.1159/000369714>
- Gan L, Li C, Wang J, Guo X (2016) Curcumin modulates the effect of histone modification on the expression of chemokines by type II alveolar epithelial cells in a rat COPD model. *Int J Chron Obstruct Pulmon Dis* 11:2765–2773. <https://doi.org/10.2147/copd.s113978>
- Ganjali S, Blesso CN, Banach M, Pirro M, Majeed M, Sahebkar A (2017a) Effects of curcumin on HDL functionality. *Pharmacol Res* 119:208–218. <https://doi.org/10.1016/j.phrs.2017.02.008>
- Ganjali S, Blesso CN, Banach M, Pirro M, Majeed M, Sahebkar A (2017b) Effects of curcumin on HDL functionality (review). *Pharmacol Res* 119:208–218. <https://doi.org/10.1016/j.phrs.2017.02.008>
- Ghasemi F, Bagheri H, Barreto GE, Read MI, Sahebkar A (2019) Effects of curcumin on microglial cells (review). *Neurotox Res* 36(1):12–26. <https://doi.org/10.1007/s12640-019-00030-0>
- Ghosh N, Ghosh R, Mandal V, Mandal SC (2011) Recent advances in herbal medicine for treatment of liver diseases. *Pharm Biol* 49(9):970–988
- Ghosh S, Banerjee S, Sil PC (2015) The beneficial role of curcumin on inflammation, diabetes and neurodegenerative disease: a recent update. *Food Chem Toxicol* 83:111–124
- Goel A, Jhurani S, Aggarwal BB (2008a) Multi-targeted therapy by curcumin: how spicy is it? *Mol Nutr Food Res* 52(9):1010–1030. <https://doi.org/10.1002/mnfr.200700354>
- Goel A, Kunnumakkara AB, Aggarwal BB (2008b) Curcumin as “Curecumin”: from kitchen to clinic. *Biochem Pharmacol* 75(4):787–809. <https://doi.org/10.1016/j.bcp.2007.08.016>
- Gong P, Liu M, Hong G, Li Y, Xue P, Zheng M et al (2016) Curcumin improves LPS-induced preeclampsia-like phenotype in rat by inhibiting the TLR4 signaling pathway. *Placenta* 41:45–52. <https://doi.org/10.1016/j.placenta.2016.03.002>
- Gouda MM, Bhandary YP (2018) Curcumin down-regulates IL-17A mediated p53-fibrinolytic system in bleomycin induced acute lung injury in vivo. *J Cell Biochem* 119(9):7285–7299. <https://doi.org/10.1002/jcb.27026>

- Guo L, Xing Y, Pan R, Jiang M, Gong Z, Lin L et al (2013) Curcumin protects microglia and primary rat cortical neurons against HIV-1 gp120-mediated inflammation and apoptosis. *PLoS ONE* 8(8):e70565. <https://doi.org/10.1371/journal.pone.0070565>
- Gustavsson M (2020) New insights into the structure and function of chemokine receptor: chemokine complexes from an experimental perspective. *J Leukocyte Biol* 2:2
- Hassanzadeh S, Read MI, Bland AR, Majeed M, Jamialahmadi T, Sahebkar A (2020) Curcumin: an inflammasome silencer (review). *Pharmacol Res* 159:2. <https://doi.org/10.1016/j.phrs.2020.104921>
- Heidari Z, Daei M, Boozari M, Jamialahmadi T, Sahebkar A (2022) Curcumin supplementation in pediatric patients: a systematic review of current clinical evidence (review). *Phytother Res* 36(4):1442–1458. <https://doi.org/10.1002/ptr.7350>
- Herman JG, Stadelman HL, Roselli CE (2009) Curcumin blocks CCL2-induced adhesion, motility and invasion, in part, through down-regulation of CCL2 expression and proteolytic activity. *Int J Oncol* 34(5):1319–1327
- Howells LM, Iwuji COO, Irving GRB, Barber S, Walter H, Sidat Z et al (2019) Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. *J Nutr* 149(7):1133–1139. <https://doi.org/10.1093/jn/nxz029>
- Huang R, Liu Y, Xiong Y, Wu H, Wang G, Sun Z et al (2016) Curcumin protects against liver fibrosis by attenuating infiltration of Gr1hi monocytes through inhibition of monocyte chemoattractant protein-1. *Discov Med* 21(118):447–457
- Hwang YP, Jin SW, Choi JH, Choi CY, Kim HG, Kim SJ et al (2017) Inhibitory effects of l-theanine on airway inflammation in ovalbumin-induced allergic asthma. *Food Chem Toxicol* 99:162–169. <https://doi.org/10.1016/j.fct.2016.11.032>
- Iranshahi M, Sahebkar A, Takasaki M, Konoshima T, Tokuda H (2009) Cancer chemopreventive activity of the prenylated coumarin, umbelliprenin, in vivo (Article). *Eur J Cancer Prev* 18(5):412–415. <https://doi.org/10.1097/CEJ.0b013e32832c389e>
- Jacob A, Chaves L, Eadon MT, Chang A, Quigg RJ, Alexander JJ (2013) Curcumin alleviates immune-complex-mediated glomerulonephritis in factor-H-deficient mice. *Immunology* 139(3):328–337. <https://doi.org/10.1111/imm.12079>
- Jain SK, Rains J, Croad J, Larson B, Jones K (2009) Curcumin supplementation lowers TNF- α , IL-6, IL-8, and MCP-1 secretion in high glucose-treated cultured monocytes and blood levels of TNF- α , IL-6, MCP-1, glucose, and glycosylated hemoglobin in diabetic rats. *Antioxid Redox Signal* 11(2):241–249. <https://doi.org/10.1089/ars.2008.2140>
- Jennings MR, Parks RJ (2020) Curcumin as an antiviral agent. *Viruses* 12(11):1242
- Ji RR, Gereau RW, Malcangio M, Strichartz GR (2009) MAP kinase and pain. *Brain Res Rev* 60(1):135–148. <https://doi.org/10.1016/j.brainresrev.2008.12.011>
- Jia S, Xie P, Hong SJ, Galiano R, Singer A, Clark RA et al (2014) Intravenous curcumin efficacy on healing and scar formation in rabbit ear wounds under nonischemic, ischemic, and ischemia-reperfusion conditions. *Wound Repair Regen* 22(6):730–739. <https://doi.org/10.1111/wrr.12231>
- Jones EA, Shahed A, Shoskes DA (2000) Modulation of apoptotic and inflammatory genes by bioflavonoids and angiotensin II inhibition in ureteral obstruction. *Urology* 56(2):346–351. [https://doi.org/10.1016/s0090-4295\(00\)00608-7](https://doi.org/10.1016/s0090-4295(00)00608-7)
- Karimian MS, Pirro M, Majeed M, Sahebkar A (2017a) Curcumin as a natural regulator of monocyte chemoattractant protein-1. *Cytokine Growth Factor Rev* 33:55–63
- Kaur H, Patro I, Tikoo K, Sandhir R (2015) Curcumin attenuates inflammatory response and cognitive deficits in experimental model of chronic epilepsy. *Neurochem Int* 89:40–50. <https://doi.org/10.1016/j.neuint.2015.07.009>
- Kaya P, Lee SR, Lee YH, Kwon SW, Yang H, Lee HW et al (2019) Curcuma radix extract decreases mammary tumor-derived lung metastasis via suppression of C–C chemokine receptor type 7 expression. *Nutrients*. <https://doi.org/10.3390/nu11020410>
- Kebir H, Kreyenborg K, Ifergan I, Dodelet-Devillers A, Cayrol R, Bernard M et al (2007) Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. *Nat Med* 13(10):1173–1175. <https://doi.org/10.1038/nm1651>
- Killian PH, Kronski E, Michalik KM, Barbieri O, Astigiano S, Sommerhoff CP et al (2012) Curcumin inhibits prostate cancer metastasis in vivo by targeting the inflammatory cytokines CXCL1 and -2. *Carcinogenesis* 33(12):2507–2519. <https://doi.org/10.1093/carcin/bgs312>
- Kim GY, Kim KH, Lee SH, Yoon MS, Lee HJ, Moon DO et al (2005) Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF- κ B as potential targets. *J Immunol* 174(12):8116–8124. <https://doi.org/10.4049/jimmunol.174.12.8116>
- Kim J, Jeong SW, Quan H, Jeong CW, Choi JI, Bae HB (2016) Effect of curcumin (*Curcuma longa* extract) on LPS-induced acute lung injury is mediated by the activation of AMPK. *J Anesth* 30(1):100–108. <https://doi.org/10.1007/s00540-015-2073-1>
- Kirovski G, Gäbele E, Dorn C, Moleda L, Niessen C, Weiss TS et al (2010) Hepatic steatosis causes induction of the chemokine RANTES in the absence of significant hepatic inflammation. *Int J Clin Exp Pathol* 3(7):675–680
- Kitagawa K, Wada T, Furuichi K, Hashimoto H, Ishiwata Y, Asano M et al (2004) Blockade of CCR2 ameliorates progressive fibrosis in kidney. *Am J Pathol* 165(1):237–246. [https://doi.org/10.1016/s0002-9440\(10\)63292-0](https://doi.org/10.1016/s0002-9440(10)63292-0)
- Kloesch B, Gober L, Loebisch S, Vcelar B, Helson L, Steiner G (2016) In vitro study of a liposomal curcumin formulation (Lipocur™): toxicity and biological activity in synovial fibroblasts and macrophages. *In Vivo* 30(4):413–419
- Kobayashi SD, DeLeo FR (2009) Role of neutrophils in innate immunity: a systems biology-level approach. *Wiley Interdiscip Rev Syst Biol Med* 1(3):309–333. <https://doi.org/10.1002/wsbm.32>
- Konduru AS, Lee BC, Li JD (2016) Curcumin suppresses NTHi-induced CXCL5 expression via inhibition of positive IKK β pathway and up-regulation of negative MKP-1 pathway. *Sci Rep* 6:31695. <https://doi.org/10.1038/srep31695>
- Kronski E, Fiori ME, Barbieri O, Astigiano S, Mirisola V, Killian PH et al (2014) miR181b is induced by the chemopreventive polyphenol curcumin and inhibits breast cancer metastasis via down-regulation of the inflammatory cytokines CXCL1 and -2. *Mol Oncol* 8(3):581–595. <https://doi.org/10.1016/j.molonc.2014.01.005>
- Kumar P, Sulakhiya K, Barua CC, Mundhe N (2017) TNF- α , IL-6 and IL-10 expressions, responsible for disparity in action of curcumin against cisplatin-induced nephrotoxicity in rats. *Mol Cell Biochem* 431(1–2):113–122. <https://doi.org/10.1007/s11010-017-2981-5>
- Kunnumakkara AB, Diagaradjane P, Anand P, Harikumar KB, Deorukhkar A, Gelovani J et al (2009) Curcumin sensitizes human colorectal cancer to capecitabine by modulation of cyclin D1, COX-2, MMP-9, VEGF and CXCR4 expression in an orthotopic mouse model. *Int J Cancer* 125(9):2187–2197. <https://doi.org/10.1002/ijc.24593>
- Larmonier CB, Midura-Kiela MT, Ramalingam R, Laubitiz D, Janikashvili N, Larmonier N et al (2011) Modulation of neutrophil motility by curcumin: implications for inflammatory bowel disease. *Inflamm Bowel Dis* 17(2):503–515. <https://doi.org/10.1002/ibd.21391>

- Lee KW, Kim JH, Lee HJ, Surh YJ (2005) Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-kappaB transcriptional activity in MCF10A human breast epithelial cells. *Antioxid Redox Signal* 7(11–12):1612–1620. <https://doi.org/10.1089/ars.2005.7.1612>
- Legler DF, Uetz-von Allmen E, Hauser MA (2014) CCR7: roles in cancer cell dissemination, migration and metastasis formation. *Int J Biochem Cell Biol* 54:78–82. <https://doi.org/10.1016/j.biocel.2014.07.002>
- Lelli D, Sahebkar A, Johnston TP, Pedone C (2017) Curcumin use in pulmonary diseases: state of the art and future perspectives. *Pharmacol Res* 115:133–148. <https://doi.org/10.1016/j.phrs.2016.11.017>
- Li H, Sureda A, Devkota HP, Pittalà V, Barreca D, Silva AS et al (2020) Curcumin, the golden spice in treating cardiovascular diseases. *Biotechnol Adv* 38:107343
- Lin MS, Sun YY, Chiu WT, Hung CC, Chang CY, Shie FS et al (2011) Curcumin attenuates the expression and secretion of RANTES after spinal cord injury in vivo and lipopolysaccharide-induced astrocyte reactivation in vitro. *J Neurotrauma* 28(7):1259–1269. <https://doi.org/10.1089/neu.2011.1768>
- Lin YM, Hsu CJ, Liao YY, Chou MC, Tang CH (2012) The CCL2/CCR2 axis enhances vascular cell adhesion molecule-1 expression in human synovial fibroblasts. *PLoS ONE* 7(11):e49999. <https://doi.org/10.1371/journal.pone.0049999>
- Liu XY, Song L, Wang Z (2013) CCR7: A metastasis and prognosis indicator of postoperative patients with esophageal carcinoma. *Hepatogastroenterology* 60(124):747–750. <https://doi.org/10.5754/hge12846>
- Liu T, Li C, Sun H, Luo T, Tan Y, Tian D et al (2014) Curcumin inhibits monocyte chemoattractant protein-1 expression and enhances cholesterol efflux by suppressing the c-Jun N-terminal kinase pathway in macrophage. *Inflamm Res* 63(10):841–850. <https://doi.org/10.1007/s00011-014-0758-9>
- Loukinova E, Dong G, Enamorado-Ayalya I, Thomas GR, Chen Z, Schreiber H et al (2000) Growth regulated oncogene-alpha expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. *Oncogene* 19(31):3477–3486. <https://doi.org/10.1038/sj.onc.1203687>
- Lüer S, Troller R, Aebi C (2012) Antibacterial and antiinflammatory kinetics of curcumin as a potential antimucositis agent in cancer patients. *Nutr Cancer* 64(7):975–981. <https://doi.org/10.1080/01635581.2012.713161>
- Marchese A (2014) Endocytic trafficking of chemokine receptors. *Curr Opin Cell Biol* 27:72–77
- Mashayekhi-Sardoo H, Mashayekhi-Sardoo A, Roufogalis BD, Jamialahmadi T, Sahebkar A (2021) Impact of curcumin on microsomal enzyme activities: drug interaction and chemopreventive studies (Article). *Curr Med Chem* 28(34):7122–7140. <https://doi.org/10.2174/0929867328666210329123449>
- Meng Z, Yan C, Deng Q, Gao DF, Niu XL (2013) Curcumin inhibits LPS-induced inflammation in rat vascular smooth muscle cells in vitro via ROS-relative TLR4-MAPK/NF-kB pathways. *Acta Pharmacol Sin* 34(7):901–911. <https://doi.org/10.1038/aps.2013.24>
- Midura-Kiela MT, Radhakrishnan VM, Larmonier CB, Laubit D, Ghishan FK, Kiela PR (2012) Curcumin inhibits interferon-γ signaling in colonic epithelial cells. *Am J Physiol Gastrointest Liver Physiol* 302(1):G85–96. <https://doi.org/10.1152/ajpgi.00275.2011>
- Mimche PN, Thompson E, Taramelli D, Vivas L (2012) Curcumin enhances non-opsonic phagocytosis of Plasmodium falciparum through up-regulation of CD36 surface expression on monocytes/macrophages. *J Antimicrob Chemother* 67(8):1895–1904. <https://doi.org/10.1093/jac/dks132>
- Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD et al (2005) Genes that mediate breast cancer metastasis to lung. *Nature* 436(7050):518–524. <https://doi.org/10.1038/nature03799>
- Moghaddam SJ, Barta P, Mirabolfathinejad SG, Ammar-Aouchiche Z, Garza NT, Vo TT et al (2009) Curcumin inhibits COPD-like airway inflammation and lung cancer progression in mice. *Carcinogenesis* 30(11):1949–1956. <https://doi.org/10.1093/carcin/bgp229>
- Mohajeri M, Behnam B, Cicero AF, Sahebkar A (2018) Protective effects of curcumin against aflatoxicosis: a comprehensive review. *J Cell Physiol* 233(4):3552–3577
- Mohajeri M, Bianconi V, Ávila-Rodríguez MF, Barreto GE, Jamialahmadi T, Pirro M et al (2020) Curcumin: a phytochemical modulator of estrogens and androgens in tumors of the reproductive system (Review). *Pharmacol Res*. <https://doi.org/10.1016/j.phrs.2020.104765>
- Mohammadi A, Blesso CN, Barreto GE, Banach M, Majeed M, Sahebkar A (2019) Macrophage plasticity, polarization and function in response to curcumin, a diet-derived polyphenol, as an immunomodulatory agent. *J Nutr Biochem* 66:1–16. <https://doi.org/10.1016/j.jnutbio.2018.12.005>
- Mohammed ES, El-Beih NM, El-Hussieny EA, El-Ahwany E, Hassan M, Zoheiry M (2021) Effects of free and nanoparticulate curcumin on chemically induced liver carcinoma in an animal model (Article). *Arch Med Sci* 17(1):218–227. <https://doi.org/10.5114/aoms.2020.93739>
- Momtazi-Borojeni AA, Haftcheshmeh SM, Esmaeili SA, Johnston TP, Abdollahi E, Sahebkar A (2018) Curcumin: a natural modulator of immune cells in systemic lupus erythematosus (Review). *Autoimmun Rev* 17(2):125–135. <https://doi.org/10.1016/j.autrev.2017.11.016>
- Mukherjee S, Fried A, Hussaini R, White R, Baidoo J, Yalamanchi S et al (2018) Phytosomal curcumin causes natural killer cell-dependent repolarization of glioblastoma (GBM) tumor-associated microglia/macrophages and elimination of GBM and GBM stem cells. *J Exp Clin Cancer Res* 37(1):168. <https://doi.org/10.1186/s13046-018-0792-5>
- Na HS, Cha MH, Oh D-R, Cho C-W, Rhee JH, Kim YR (2011) Protective mechanism of curcumin against *Vibrio vulnificus* infection. *FEMS Immunol Med Microbiol* 63(3):355–362
- Nagaraju GP, Zhu S, Ko JE, Ashritha N, Kandimalla R, Snyder JP et al (2015) Antiangiogenic effects of a novel synthetic curcumin analog in pancreatic cancer. *Cancer Lett* 357(2):557–565. <https://doi.org/10.1016/j.canlet.2014.12.007>
- Natarajan C, Bright JJ (2002) Curcumin inhibits experimental allergic encephalomyelitis by blocking IL-12 signaling through Janus kinase-STAT pathway in T lymphocytes. *J Immunol* 168(12):6506–6513. <https://doi.org/10.4049/jimmunol.168.12.6506>
- Ohno M, Nishida A, Sugitani Y, Nishino K, Inatomi O, Sugimoto M et al (2017) Nanoparticle curcumin ameliorates experimental colitis via modulation of gut microbiota and induction of regulatory T cells. *PLoS ONE* 12(10):e0185999. <https://doi.org/10.1371/journal.pone.0185999>
- Overbeek SA, Braber S, Koelink PJ, Henricks PA, Mortaz E, LoTam Loi AT et al (2013) Cigarette smoke-induced collagen destruction; key to chronic neutrophilic airway inflammation? *PLoS ONE* 8(1):e55612. <https://doi.org/10.1371/journal.pone.0055612>
- Pan Y, Zhang X, Wang Y, Cai L, Ren L, Tang L et al (2013a) Targeting JNK by a new curcumin analog to inhibit NF-kB-mediated expression of cell adhesion molecules attenuates renal macrophage infiltration and injury in diabetic mice. *PLoS ONE* 8(11):e79084. <https://doi.org/10.1371/journal.pone.0079084>

- Pan Y, Zhu G, Wang Y, Cai L, Cai Y, Hu J et al (2013b) Attenuation of high-glucose-induced inflammatory response by a novel curcumin derivative B06 contributes to its protection from diabetic pathogenic changes in rat kidney and heart. *J Nutr Biochem* 24(1):146–155. <https://doi.org/10.1016/j.jnutbio.2012.03.012>
- Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, Sahebkar A (2014a) Lipid-modifying effects of adjunctive therapy with curcuminoids–piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. *Complement Ther Med* 22(5):851–857
- Panahi Y, Saadat A, Beiraghdar F, Sahebkar A (2014b) Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. *Phytother Res* 28(10):1461–1467. <https://doi.org/10.1002/ptr.5149>
- Panahi Y, Ghanei M, Bashiri S, Hajhashemi A, Sahebkar A (2015a) Short-term curcuminoid supplementation for chronic pulmonary complications due to sulfur mustard intoxication: positive results of a randomized double-blind placebo-controlled trial. *Drug Res (stuttg)* 65(11):567–573. <https://doi.org/10.1055/s-0034-1389986>
- Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, Sahebkar A (2015b) Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. *Clin Nutr* 34(6):1101–1108
- Panahi Y, Khalili N, Sahebi E, Namazi S, Karimian MS, Majeed M et al (2017a) Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial. *Inflammopharmacology* 25(1):25–31. <https://doi.org/10.1007/s10787-016-0301-4>
- Panahi Y, Khalili N, Sahebi E, Namazi S, Reiner Ž, Majeed M et al (2017b) Curcuminoids modify lipid profile in type 2 diabetes mellitus: a randomized controlled trial (Article). *Complement Ther Med* 33:1–5. <https://doi.org/10.1016/j.ctim.2017.05.006>
- Parsamanesh N, Moossavi M, Bahrami A, Butler AE, Sahebkar A (2018) Therapeutic potential of curcumin in diabetic complications (review). *Pharmacol Res* 136:181–193. <https://doi.org/10.1016/j.phrs.2018.09.012>
- Peled A, Wald O, Burger J (2012) Development of novel CXCR4-based therapeutics. *Expert Opin Investig Drugs* 21(3):341–353. <https://doi.org/10.1517/13543784.2012.656197>
- Pellicoro A, Ramachandran P, Iredale JP, Fallowfield JA (2014) Liver fibrosis and repair: immune regulation of wound healing in a solid organ. *Nat Rev Immunol* 14(3):181–194. <https://doi.org/10.1038/nri3623>
- Pickich MB, Hargrove MW, Phillips CN, Healy JC, Moore AN, Roberts MD et al (2019) Effect of curcumin supplementation on serum expression of select cytokines and chemokines in a female rat model of nonalcoholic steatohepatitis. *BMC Res Notes* 12(1):496. <https://doi.org/10.1186/s13104-019-4540-5>
- Pourbagher-Shahri AM, Farkhondeh T, Ashrafzadeh M, Talebi M, Samargahndian S (2021) Curcumin and cardiovascular diseases: focus on cellular targets and cascades. *Biomed Pharmacother* 136:111214
- Prasad S, Gupta SC, Tyagi AK, Aggarwal BB (2014) Curcumin, a component of golden spice: from bedside to bench and back. *Biotechnol Adv* 32(6):1053–1064
- Proudfoot AE, Uguccioni M (2016) Modulation of chemokine responses: synergy and cooperativity. *Front Immunol* 7:183
- Qadir MI, Naqvi ST, Muhammad SA (2016) Curcumin: a polyphenol with molecular targets for cancer control. *Asian Pac J Cancer Prev* 17(6):2735–2739
- Qin L, Qin J, Zhen X, Yang Q, Huang L (2018) Curcumin protects against hepatic stellate cells activation and migration by inhibiting the CXCL12/CXCR4 biological axis in liver fibrosis: a study in vitro and in vivo. *Biomed Pharmacother* 101:599–607. <https://doi.org/10.1016/j.biopha.2018.02.091>
- Qureshi M, Al-Suhaimi EA, Wahid F, Shehzad O, Shehzad A (2018) Therapeutic potential of curcumin for multiple sclerosis. *Neurol Sci* 39(2):207–214. <https://doi.org/10.1007/s10072-017-3149-5>
- Rai D, Singh JK, Roy N, Panda D (2008) Curcumin inhibits FtsZ assembly: an attractive mechanism for its antibacterial activity. *Biochemical Journal* 410(1):147–155
- Rajagopal S, Rajagopal K, Lefkowitz RJ (2010) Teaching old receptors new tricks: biasing seven-transmembrane receptors. *Nat Rev Drug Discovery* 9(5):373–386
- Rakariyatham K, Du Z, Yuan B, Gao Z, Song M, Pan C et al (2019) Inhibitory effects of 7,7'-bromo-curcumin on 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation. *Eur J Pharmacol* 858:172479. <https://doi.org/10.1016/j.ejphar.2019.172479>
- Ransohoff RM, Kivisäkk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. *Nat Rev Immunol* 3(7):569–581. <https://doi.org/10.1038/nri1130>
- Röhl C, Lucius R, Sievers J (2007) The effect of activated microglia on astrogliosis parameters in astrocyte cultures. *Brain Res* 1129(1):43–52. <https://doi.org/10.1016/j.brainres.2006.10.057>
- Ruiz de Porras V, Bystrup S, Martínez-Cardús A, Pluvinet R, Sumoy L, Howells L et al (2016) Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXCL12-Chemokine/NF-κB signalling pathway. *Sci Rep* 6:24675. <https://doi.org/10.1038/srep24675>
- Ruparelina N, Chai JT, Fisher EA, Choudhury RP (2017) Inflammatory processes in cardiovascular disease: a route to targeted therapies. *Nat Rev Cardiol* 14(3):133–144. <https://doi.org/10.1038/nrcardio.2016.185>
- Sahebkar A, Henrotin Y (2016) Analgesic efficacy and safety of curcuminoids in clinical practice: a systematic review and meta-analysis of randomized controlled trials (Review). *Pain Medicine (United States)* 17(6):1192–1202. <https://doi.org/10.1093/pm/pnv024>
- Sakai H, Kai Y, Oguchi A, Kimura M, Tabata S, Yaegashi M et al (2016) Curcumin inhibits 5-fluorouracil-induced up-regulation of CXCL1 and CXCL2 of the colon associated with attenuation of diarrhoea development. *Basic Clin Pharmacol Toxicol* 119(6):540–547. <https://doi.org/10.1111/bcpt.12619>
- Sameermahmood Z, Balasubramanyam M, Saravanan T, Rema M (2008) Curcumin modulates SDF-1α/CXCR4-induced migration of human retinal endothelial cells (HRECs). *Invest Ophthalmol Vis Sci* 49(8):3305–3311. <https://doi.org/10.1167/iovs.07-0456>
- Santos AM, Lopes T, Oleastro M, Gato IV, Floch P, Benejat L et al (2015) Curcumin inhibits gastric inflammation induced by *Helicobacter pylori* infection in a mouse model. *Nutrients* 7(1):306–320. <https://doi.org/10.3390/nu7010306>
- Scholten DJ, Canals M, Maussang D, Roumen L, Smit MJ, Wijnmans M et al (2012) Pharmacological modulation of chemokine receptor function. *Br J Pharmacol* 165(6):1617–1643
- Seki E, De Minicis S, Gwak GY, Kluwe J, Inokuchi S, Bursill CA et al (2009) CCR1 and CCR5 promote hepatic fibrosis in mice. *J Clin Invest* 119(7):1858–1870. <https://doi.org/10.1172/jci37444>
- Seyedzadeh MH, Safari Z, Zare A, Gholizadeh Navashenaq J, Razavi SA, Kardar GA et al (2014) Study of curcumin immunomodulatory effects on reactive astrocyte cell function. *Int Immunopharmacol* 22(1):230–235. <https://doi.org/10.1016/j.intimp.2014.06.035>
- Shahid H, Shahzad M, Shabbir A, Saghir G (2019) Immunomodulatory and anti-inflammatory potential of curcumin for the treatment of allergic asthma: effects on expression levels of pro-inflammatory cytokines and aquaporins. *Inflammation* 42(6):2037–2047. <https://doi.org/10.1007/s10753-019-01066-2>

- Shishodia S (2013) Molecular mechanisms of curcumin action: gene expression. *BioFactors* 39(1):37–55. <https://doi.org/10.1002/biof.1041>
- Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R (2005) Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of I κ B kinase and nuclear factor κ B activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. *Cancer* 104(4):879–890. <https://doi.org/10.1002/ncr.21216>
- Skommer J, Wlodkovic D, Pelkonen J (2007) Gene-expression profiling during curcumin-induced apoptosis reveals downregulation of CXCR4. *Exp Hematol* 35(1):84–95. <https://doi.org/10.1016/j.exphem.2006.09.006>
- Soetikno V, Sari FR, Veeraveedu PT, Thandavarayan RA, Harima M, Sukumaran V et al (2011) Curcumin ameliorates macrophage infiltration by inhibiting NF- κ B activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. *Nutr Metab (Iond)* 8(1):35. <https://doi.org/10.1186/1743-7075-8-35>
- Solito E, Sastre M (2012) Microglia function in Alzheimer's disease. *Front Pharmacol* 3:14. <https://doi.org/10.3389/fphar.2012.00014>
- Soltani S, Boozari M, Cicero AFG, Jamialahmadi T, Sahebkar A (2021) Effects of phytochemicals on macrophage cholesterol efflux capacity: impact on atherosclerosis (review). *Phytother Res* 35(6):2854–2878. <https://doi.org/10.1002/ptr.6991>
- Sun X, Liu Y, Li C, Wang X, Zhu R, Liu C et al (2017) Recent advances of curcumin in the prevention and treatment of renal fibrosis. *Biomed Res Int* 2017:2418671. <https://doi.org/10.1155/2017/2418671>
- Sundaram JR, Poore CP, Sulaimi NHB, Pareek T, Cheong WF, Wenk MR et al (2017) Curcumin ameliorates neuroinflammation, neurodegeneration, and memory deficits in p25 transgenic mouse model that bears hallmarks of Alzheimer's disease. *J Alzheimers Dis* 60(4):1429–1442. <https://doi.org/10.3233/jad-170093>
- Surh YJ, Chun KS, Cha HH, Han SS, Keum YS, Park KK et al (2001) Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF- κ B activation. *Mutat Res* 480–481:243–268. [https://doi.org/10.1016/s0027-5107\(01\)00183-x](https://doi.org/10.1016/s0027-5107(01)00183-x)
- Teow S-Y, Liew K, Ali SA, Khoo AS-B, Peh S-C (2016) Antibacterial action of curcumin against *Staphylococcus aureus*: a brief review. *J Trop Med* 2016(2):1
- Tham CL, Hazeera Harith H, Wai Lam K, Joong Chong Y, Singh Cheema M, Roslan Sulaiman M et al (2015) The synthetic curcuminoid BHMC restores endotoxin-stimulated HUVEC dysfunction: specific disruption on enzymatic activity of p38 MAPK. *Eur J Pharmacol* 749:1–11. <https://doi.org/10.1016/j.ejphar.2014.12.015>
- Tomeh MA, Hadianamrei R, Zhao X (2019) A review of curcumin and its derivatives as anticancer agents. *Int J Mol Sci* 20(5):1033
- Tremmel L, Rho O, Slaga TJ, DiGiovanni J (2019) Inhibition of skin tumor promotion by TPA using a combination of topically applied ursolic acid and curcumin. *Mol Carcinog* 58(2):185–195. <https://doi.org/10.1002/mc.22918>
- Tu CT, Han B, Liu HC, Zhang SC (2011) Curcumin protects mice against concanavalin A-induced hepatitis by inhibiting intrahepatic intercellular adhesion molecule-1 (ICAM-1) and CXCL10 expression. *Mol Cell Biochem* 358(1–2):53–60. <https://doi.org/10.1007/s11010-011-0920-4>
- Tu CT, Yao QY, Xu BL, Wang JY, Zhou CH, Zhang SC (2012) Protective effects of curcumin against hepatic fibrosis induced by carbon tetrachloride: modulation of high-mobility group box 1, Toll-like receptor 4 and 2 expression. *Food Chem Toxicol* 50(9):3343–3351. <https://doi.org/10.1016/j.fct.2012.05.050>
- Ueki M, Ueno M, Morishita J, Maekawa N (2013) Curcumin ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice. *J Biosci Bioeng* 115(5):547–551. <https://doi.org/10.1016/j.jbiosc.2012.11.007>
- Vahedian-Azimi A, Abbasifard M, Rahimi-Bashar F, Guest PC, Majeed M, Mohammadi A et al (2022) Effectiveness of curcumin on outcomes of hospitalized COVID-19 patients: a systematic review of clinical trials (review). *Nutrients*. <https://doi.org/10.3390/nu14020256>
- Vera-Ramirez L, Pérez-Lopez P, Varela-Lopez A, Ramirez-Tortosa M, Battino M, Quiles JL (2013) Curcumin and liver disease. *BioFactors* 39(1):88–100
- Vezzani A, Auvin S, Ravizza T, Aronica E (2012) Glia-neuronal interactions in ictogenesis and epileptogenesis: role of inflammatory mediators. In: Noebels JL, Avoli M, Rogawski MA, Olsen RW, Delgado-Escueta AV (eds) *Jasper's Basic Mechanisms of the Epilepsies* Bethesda MD: © 2012, Michael A Rogawski, Antonio V Delgado-Escueta, Jeffrey L Noebels, Massimo Avoli and Richard W Olsen
- Vitali D, Bagri P, Wessels JM, Arora M, Ganugula R, Parikh A et al (2020) Curcumin can decrease tissue inflammation and the severity of hsv-2 infection in the female reproductive mucosa. *Int J Mol Sci*. <https://doi.org/10.3390/ijms21010337>
- Wada T, Furuichi K, Sakai N, Iwata Y, Kitagawa K, Ishida Y et al (2004) Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fibrosis. *J Am Soc Nephrol* 15(4):940–948. <https://doi.org/10.1097/01.asn.0000120371.09769.80>
- Walker L, Sills GJ (2012) Inflammation and epilepsy: the foundations for a new therapeutic approach in epilepsy? *Epilepsy Curr* 12(1):8–12. <https://doi.org/10.5698/1535-7511-12.1.8>
- Wang D, Sun H, Wei J, Cen B, DuBois RN (2017a) CXCL1 is critical for premetastatic niche formation and metastasis in colorectal cancer. *Cancer Res* 77(13):3655–3665. <https://doi.org/10.1158/0008-5472.can-16-3199>
- Wang Y, Yin Z, Gao L, Sun D, Hu X, Xue L et al (2017b) Curcumin delays retinal degeneration by regulating microglia activation in the retina of rd1 mice. *Cell Physiol Biochem* 44(2):479–493. <https://doi.org/10.1159/000485085>
- Xiaoling MU, Jing Z, Fang X, Liangdan T (2010) Curcumin inhibits invasion and metastasis in the human ovarian cancer cells SKOV3 by CXCL12-CXCR4 axis (Article). *Afr J Biotechnol* 9(48):8230–8234. <https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649836793&partnerID=40&md5=b306054ad8b73fee808ad8cd6d86ccb0>
- Xie L, Li XK, Funeshima-Fuji N, Kimura H, Matsumoto Y, Isaka Y et al (2009) Amelioration of experimental autoimmune encephalomyelitis by curcumin treatment through inhibition of IL-17 production. *Int Immunopharmacol* 9(5):575–581. <https://doi.org/10.1016/j.intimp.2009.01.025>
- Xie L, Li XK, Takahara S (2011) Curcumin has bright prospects for the treatment of multiple sclerosis. *Int Immunopharmacol* 11(3):323–330. <https://doi.org/10.1016/j.intimp.2010.08.013>
- Xu F, Diao R, Liu J, Kang Y, Wang X, Shi L (2015) Curcumin attenuates staphylococcus aureus-induced acute lung injury. *Clin Respir J* 9(1):87–97. <https://doi.org/10.1111/crj.12113>
- Yadollahi A, Zargaran B (2019) The beneficial effects of curcumin on cardiovascular diseases and their risk factors. *Rev Clin Med* 6(1):12–19
- Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. *Am J Med Sci* 334(2):115–124. <https://doi.org/10.1097/MAJ.0b013e31812df1e>

- Young NA, Bruss MS, Gardner M, Willis WL, Mo X, Valiente GR et al (2014) Oral administration of nano-emulsion curcumin in mice suppresses inflammatory-induced NF κ B signaling and macrophage migration. *PLoS ONE* 9(11):e111559. <https://doi.org/10.1371/journal.pone.0111559>
- Youngs SJ, Ali SA, Taub DD, Rees RC (1997) Chemokines induce migrational responses in human breast carcinoma cell lines. *Int J Cancer* 71(2):257–266. [https://doi.org/10.1002/\(sici\)1097-0215\(19970410\)71:2%3c257::aid-ijc22%3e3.0.co;2-d](https://doi.org/10.1002/(sici)1097-0215(19970410)71:2%3c257::aid-ijc22%3e3.0.co;2-d)
- Yu Y, Sun J, Wang R, Liu J, Wang P, Wang C (2019) Curcumin management of myocardial fibrosis and its mechanisms of action: a review. *Am J Chin Med* 47(08):1675–1710
- Yuan J, Liu W, Zhu H, Chen Y, Zhang X, Li L et al (2017) Curcumin inhibits glial scar formation by suppressing astrocyte-induced inflammation and fibrosis in vitro and in vivo. *Brain Res* 1655:90–103. <https://doi.org/10.1016/j.brainres.2016.11.002>
- Zhang ZJ, Zhao LX, Cao DL, Zhang X, Gao YJ, Xia C (2012) Curcumin inhibits LPS-induced CCL2 expression via JNK pathway in C6 rat astrocytoma cells. *Cell Mol Neurobiol* 32(6):1003–1010. <https://doi.org/10.1007/s10571-012-9816-4>
- Zhang Z, Chen H, Xu C, Song L, Huang L, Lai Y et al (2016) Curcumin inhibits tumor epithelial-mesenchymal transition by down-regulating the Wnt signaling pathway and upregulating NKD2 expression in colon cancer cells. *Oncol Rep* 35(5):2615–2623. <https://doi.org/10.3892/or.2016.4669>
- Zhang ZY, Jiang M, Fang J, Yang MF, Zhang S, Yin YX et al (2017) Enhanced therapeutic potential of nano-curcumin against subarachnoid hemorrhage-induced blood-brain barrier disruption through inhibition of inflammatory response and oxidative stress. *Mol Neurobiol* 54(1):1–14. <https://doi.org/10.1007/s12035-015-9635-y>
- Zhang L, Wang X, Zhang L, Virgous C, Si H (2019) Combination of curcumin and luteolin synergistically inhibits TNF- α -induced vascular inflammation in human vascular cells and mice. *J Nutr Biochem* 73:108222. <https://doi.org/10.1016/j.jnutbio.2019.108222>
- Zhao LX, Jiang BC, Wu XB, Cao DL, Gao YJ (2014) Ligustilide attenuates inflammatory pain via inhibition of NF κ B-mediated chemokines production in spinal astrocytes. *Eur J Neurosci* 39(8):1391–1402. <https://doi.org/10.1111/ejn.12502>
- Zhao F, Gong Y, Hu Y, Lu M, Wang J, Dong J et al (2015) Curcumin and its major metabolites inhibit the inflammatory response induced by lipopolysaccharide: translocation of nuclear factor- κ B as potential target. *Mol Med Rep* 11(4):3087–3093. <https://doi.org/10.3892/mmr.2014.3079>
- Zhao XA, Chen G, Liu Y, Chen Y, Wu H, Xiong Y et al (2018) Curcumin reduces Ly6C(hi) monocyte infiltration to protect against liver fibrosis by inhibiting Kupffer cells activation to reduce chemokines secretion. *Biomed Pharmacother* 106:868–878. <https://doi.org/10.1016/j.biopha.2018.07.028>
- Zhong F, Chen H, Han L, Jin Y, Wang W (2011) Curcumin attenuates lipopolysaccharide-induced renal inflammation. *Biol Pharm Bull* 34(2):226–232. <https://doi.org/10.1248/bpb.34.226>
- Zhong Y, Liu T, Guo Z (2012) Curcumin inhibits ox-LDL-induced MCP-1 expression by suppressing the p38MAPK and NF- κ B pathways in rat vascular smooth muscle cells. *Inflamm Res* 61(1):61–67. <https://doi.org/10.1007/s00011-011-0389-3>
- Zhong Y, Liu T, Lai W, Tan Y, Tian D, Guo Z (2013) Heme oxygenase-1-mediated reactive oxygen species reduction is involved in the inhibitory effect of curcumin on lipopolysaccharide-induced monocyte chemoattractant protein-1 production in RAW264.7 macrophages. *Mol Med Rep* 7(1):242–246. <https://doi.org/10.3892/mmr.2012.1138>
- Zhou H, Beevers CS, Huang S (2011) The targets of curcumin. *Curr Drug Targets* 12(3):332–347. <https://doi.org/10.2174/138945011794815356>
- Zhou J, Miao H, Li X, Hu Y, Sun H, Hou Y (2017) Curcumin inhibits placental inflammation to ameliorate LPS-induced adverse pregnancy outcomes in mice via upregulation of phosphorylated Akt. *Inflamm Res* 66(2):177–185. <https://doi.org/10.1007/s00011-016-1004-4>
- Zhu T, Chen Z, Chen G, Wang D, Tang S, Deng H et al (2019) Curcumin attenuates asthmatic airway inflammation and mucus hypersecretion involving a PPAR γ -dependent NF- κ B signaling pathway in vivo and in vitro. *Mediators Inflamm* 2019:4927430. <https://doi.org/10.1155/2019/4927430>
- Zhuo C, Wu X, Li J, Hu D, Jian J, Chen C et al (2018) Chemokine (C-X-C motif) ligand 1 is associated with tumor progression and poor prognosis in patients with colorectal cancer. *Biosci Rep*. <https://doi.org/10.1042/bsr20180580>
- Ziaei A, Hoppstädter J, Kiemer AK, Ramezani M, Amirghofran Z, Diesel B (2015) Inhibitory effects of teuclatriol, a sesquiterpene from *salvia mirzayanii*, on nuclear factor- κ B activation and expression of inflammatory mediators. *J Ethnopharmacol* 160:94–100. <https://doi.org/10.1016/j.jep.2014.10.041>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.